8 Reasons Online Dating Sites Are a Business Dead End

  • 8 Reasons Online Dating Sites Are a Business Dead End
  • LTD Commodities | Gifts, Unique Finds, Home Decor, Storage
  • Celebs Go Dating 2019 cast, news, Tom, Eden and Nadia
  • Go dating ltd - informepastran.com
  • GO DATING LTD - Officers (free information from Companies
What happened to Christine Markey? The 22-year-old disappeared from Oneida, NY on Jan. 10th, 1993, following an argument with her girlfriend over infidelity. Despite the suspicious circumstances, the case has been cold for 27 years with few leads.

I have found a handful of articles on this disappearance but accounts vary depend on which one you read. I’ve tried to compile all the information in order of how it was reported from various sources.
22-year-old Christine Markey of Oneida, New York, was reported missing on January 15th, 1993, by her father, Philip Markey. Markey was last seen at her Elizabeth Street apartment on Sunday, January 10th, 1993, according to her roommate when she was initially. Her roommate, Tracy L. Taber, 22, said she last saw Markey at 8:30am that morning wearing stretch pants and a T-shirt. Taber claimed to have left the apartment for two hours, and returned to Markey being gone. The two were planning to go apartment hunting later that day. A February 1993 interview quotes Taber, “It bothers me a lot. We’ve been roommates for close to six years now. I don’t think she’s out gallivanting around. I think something’s going on. I think something’s happened.”
As the investigation continued, police discovered more information on the relationship between Markey and Taber, and a later article on the case quoted, “Police say Christine Markey and her live-in girlfriend, Tracy L. Taber, had an on-again off-again romancing spanning a number of years. And although the couple kept many of their troubles to themselves, cops say their investigation showed the couple was far from perfect.”
At this point, Taber was now a person of interest to police.
Further investigating revealed a previously undisclosed altercation involving the couple that happened the night previous to Markey’s last reported whereabouts.
Prior to the 10th, Tracy Taber learned of Christine Markey’s secret relationship involving someone she’d met at a bar, Robert Gibson Mailloux. The two had supposedly been dating for about a month.
According to police and by the account of Mailloux, the night prior (Jan. 9th) to Markey’s disappearance, an argument between Taber and Markey took place at the two women’s Elizabeth Street apartment. The argument was about the secret relationship between Markey and Mailloux; the two yelled profanities at one another, while Mailloux, who was accompanied by a male friend were present and listened. At some point, Markey and Mailloux left the apartment and went to a local Oneida bar near Phelps Street. As the pair were leaving the bar, Taber pulled up in her car and demanded that Markey get in. During this interaction, Mailloux recounted that Taber threatened him saying, “you’ll never see Chris (Christine Markey) again”. Markey got into the car and Mailloux never saw her again.
After picking her up in the early morning hours of January 10th, witnesses saw Markey and Taber entering their apartment but not coming out.
Later in the day on the 10th, witnesses spotted Tracey Taber, along with her father, Mike Taber, moving boxes from the apartment on Elizabeth Street.
Though the sighting during the early morning hours of the 10th is believed to be her last known movements, the landlord of the two women’s 474 Elizabeth Street apartment believes to have seen Markey and Taber going into their apartment on January 11th.
This sighting shreds doubt on Taber’s original report that she last saw Christine at 8:30am the morning of January 10th. Though this is inconsistency casts suspicion over Taber as to why she would lie.
Though Markey’s landlord would know have been able to accurately identified her walking into her apartment on the 11th, the 11th was a Monday and it isn’t reportedly that Markey went to work that day. Furthermore, Markey never picked up her last paychecks from either of her two jobs, one of which was at the Oneida Ltd.
Along with her paycheck’s never being picked up, Markey’s social security numbered has never been used, it never appeared that she took any personal belongings with her if she left willingly, and no sighting of her has been reported in the 27 years following her disappearance. These facts and the circumstances prior to her disappearance label her as an Endangered Missing Persons.
It’s reported that Christine Markey had several run-ins with the law prior to her disappearance, research brought up no reports on what specifically from what I could find. Despite this, her father stated that at the time she had been doing well in the years prior before her disappearance and had attended business and real estate classes at Morrisville State College.
Christine Markey’s boyfriend at the time, Robert Mailloux, was questioned and ruled out as a suspect back in 1993. Oneida police have indicated they would like to speak with him again but are unable to locate him.
I discovered that Tracey Taber, who remained a person of interest in the case throughout the years, passed away at 48-years-old on November 18th, 2018. She maintained her innocence always.
NamUs indicates that is does not have Christine’s DNA nor any family members DNA to match to any Jane Doe’s or remains discovered, which is a shame.
If Christine were alive today she would be 49-years-old.
Information or tips about her case can be called into the City of Oneida PD // (315) 363-9111 , with the case number being 93-0293.
NOTES & COMMENTS:
This case sent me down a rabbit hole and gave me a lot of questions. I find it very suspicious that Taber did not report Markey missing herself, as the two lived together and were still in a relationship despite the infidelity. If she really hadn’t seen Christine Markey since the morning of the 10th, you’d think she wouldn’t have waited to say something until her father reported her missing on the 15th.
The account of the landlord seeing Taber and Markey also brings up many questions for me. I would think if something horrible happened to Markey, it would have been a heat of the moment type of event, not something planned. If a witness who would have known the two women had seen them together a day after their argument, it leads me to think things got talked over and the initial hurt died down. But that doesn’t have to be the case.
Trying to consider other possibilities, I wonder if a hate crime could have occurred against Christine Markey as she was a bisexual woman in the early 90’s. It seems unlikely based on the circumstances but that did get brought to mind. Also, little information is out there regarding what the search consisted of after she vanished, so I have no idea if the police were active on the case or not.
REFERENCES:
NamUS // https://www.namus.gov/MissingPersons/Case#/696/contacts
Achieved Police Reports // https://www.oneidadispatch.com/
Charley Project // http://charleyproject.org/case/christine-marie-markey
PhilosophyofCrime // https://philosophyofcrime.com/the-disappearance-of-christine-markey/
WhereAboutsStillUnknown // https://whereaboutsstillunknown.wordpress.com/2013/04/23/christine-markey/
submitted by alwayssunnyinupstate to UnresolvedMysteries [link] [comments]

Regarding PoE Overlay and PoE Planner using Overwolf for future updates.

If you haven't already seen because of the massive amounts of down votes both threads received, the tools Poe Overlay and PoE Planner have partnered up with a company called Overwolf to develop their "Gaming Apps"
https://www.reddit.com/pathofexile/comments/gzxdqv/poe_overlay_10_release_market_replay_vulkan/
https://www.reddit.com/pathofexile/comments/gzssme/poe_planner_overwolf_beta_release/
Overwolf has a long loooong history of shady practices including data mining and targeted advertising. Some examples from their website:
Overwolf merges ad experience with positive gaming experience. We use smart ad placement and timing to reach buyers' KPIs. Ads are shown while users wait for the game to load or while they browse team stats.
An article showing Overwolf harvests your data for targeted ads:
https://news.softpedia.com/news/overwolf-software-bundled-with-teamspeak-harvesting-user-data-for-targeted-ads-528693.shtml
“When you download our client and/or register, we collect Personal Data provided by you, such as your username, email address and profile picture. If you register through a third party log-in/ account registration service (such as Facebook, Gmail, etc.), we collect your basic profile information from such third-party log-in/account registration service and your profile picture.
We also collect Personal Data when you use the Services, such as games you played, language preference, referring site, pages viewed and the order of those pages etc, or contact us with questions or complaints. When you visit our Site and/or use the Services, we automatically collect your IP address, operating system, connected device, hardware details and other information about your use of the Site and/or Services. We can receive aggregated data containing impressions, revenue, video stats, as well as confirmation of user completions.”
“We share the Personal Data we collect with our service providers and subcontractors who assist us in the operation of the Services and process the information on our behalf and under our instructions, as well as with our business partners and affiliates who may offer you products and services, based on your preferences (if you indicate your desire to receive these).”
I understand the creators of these tools rightly deserve to be compensated for the amount of time and effort they put into making these tools, but using bloated malware disguised as "a software platform designed to help developers create extensions for video games" is 100% the wrong way to go about it.
I really hope these creators can find a better way to monetize their time and effort such as patreon donations & other services that don't interact with the actual tool. I have to actively navigate to the help menu of PoE Overlay to find a small link to his patreon, put it out there more! Do what wikipedia does and have a pop up every few days asking politely to consider donating to the cause, anything would be better than selling out to a garbage company like Overwolf.
Edit: here is a snippet of Overwolf's ToS provided by NOML just adding to the pile of terrible that is Overwolf:
Collecting Information: Whenever you access or make use of any of the Website, Materials or Services, Overwolf Ltd. may collect the following types of information from you: * when you create a Member Account (as defined in clause 14 of the Terms of Use), your email address, user name and password * if you purchase merchandise, your name, email address and postal address * your purchase history and other information relating to transactions made through the Website * information contained in your correspondence with Overwolf Ltd., for example, when you send us an email * information collected during the course of your use of the Website, Materials or Services, including: * gameplay information * your credited name (if any) * ‘crash reports’ in the event that a Overwolf software crash occurs, which may include details of your Member Account, a portion of the memory state of the Overwolf app when the crash occurred and the game settings you were using * the IP address of your machine when connected to the internet, the operating system and the browser your computer uses and any search engine you are using, the date and time you are visiting, the URLs of the Website pages you visit and any telemetry details (such as speed of your connection and how well Overwolf game client is running) * information collected from third parties where you have authorized this or the information is publicly available
Use of Information: Overwolf Ltd. uses the information provided by you: * to provide the Website, Materials and Services to you * to verify your identity and verify that your Member Account is not being used by others * to market products and services to you, including contacting you via email that you may choose (or opt in) to receive. * for security and system integrity purposes * to conduct research and statistical analysis (see more in the Statistics section of this privacy notice below) * to protect and/or enforce Overwolf Ltd. legal rights and interests, including defending any claim * for any other purpose authorised by you, the Act or other applicable law * where this is necessary for Overwolf Ltd. legitimate interests * automated processes do monitor gameplay to identify cheating and fraud but human intervention is applied in the decision-making process. Information is gathered transiently for these purposes.
Overwolf Ltd. may disclose your personal information to: * any business that supports Overwolf Ltd. products or services, including any person that hosts or maintains any underlying IT system or data centre that Overwolf Ltd. use to provide the Website, Materials or Services, or to process payments * its professional advisers e.g. accountants, lawyers, auditors * any other person authorised by you * Overwolf Ltd. may disclose research and statistical analysis derived from your personal information to third parties (see more in the Statistics section of this privacy notice below).
Overwolf Ltd. also may disclose information it holds about you without your prior permission if Overwolf Ltd. reasonably believes that such disclosure is necessary to: * meet legal requirements * comply with legal process or help to maintain the law * for Overwolf Ltd. other legitimate interests
Statistics: Overwolf Ltd. may use and publish aggregate statistics and group data about those people who access or make use of any of the Website, Materials or Services and their usage of any of the Website, Materials or Services.
Protecting your personal information: Unfortunately, no data transmission over the Internet can be guaranteed as totally secure. (...)
Transfers of personal information: A business that supports our services and products may be located outside the European Economic Area (“EEA”). This may mean your personal information is held and processed outside the EEA. Please see the GDPR Terms below for further information about personal data transfers from the EEA.
Internet use: While Overwolf Ltd. takes reasonable steps to maintain secure internet connections, if you provide Overwolf Ltd. with personal information over the internet, the provision of that information is at your own risk.
submitted by tf20593 to pathofexile [link] [comments]

Pilot Briefing — Gameplay Overview

Pilot Briefing — Gameplay Overview

Gameplay Overview
Star Wars™: Squadrons is the name of our next title in a galaxy far, far away! Welcome to your first briefing, pilots. This is where you’ll learn more details about the game on the road to launch. Whether you’re eager to join the New Republic’s vanguard or fight as a titan of war for the Galactic Empire, you’ll get that chance when the game releases worldwide on October 2nd, 2020.
Made in partnership between Motive Studios, Lucasfilm Ltd., and EA, Squadrons aims to provide the deepest, most authentic starfighter experience in the Star Wars galaxy to date. You’ve likely just seen it for yourself, but if not, take a look below.
Reveal Trailer
A few years ago, our team at Motive Montreal was finishing up their work on the single-player campaign for Star Wars Battlefront™ II. During this time we (unsurprisingly) spent a lot of time playing the game. As tried and true fans, the team is incredibly passionate about Star Wars. And that passion is how the idea for this game first came to be.
Inspired by what they worked on and the community’s positive reception to the starfighter experiences, a squadron of devs built a prototype, taking learnings from Starfighter Assault and the Rogue One: VR Mission. From this, “Project Incom” was formed, and if you know your Star Wars canon well, you’ll know that the Incom Corporation was the creator of the iconic T-65B X-wing starfighter used by the Rebellion—most notably by Luke Skywalker.

Key Art
But let’s get into the game itself and start with the basics of the basics: What is Star Wars: Squadrons? It’s a first-person team-based starfighter combat game set a few months after Star Wars Episode VI: Return of the Jedi, simulating the iconic space battles from Star Wars like never before! In the wake of the destruction of the Empire’s second Death Star, the Rebel Alliance has reformed into the New Republic. Despite their climactic victory over the forest moon of Endor, though, the war is not over.
Star Wars: Squadrons gives fans a look at how the war continued throughout the galaxy after the death of the Emperor. Unlike during the years of fighting during the Galactic Civil War leading up to this point, the Empire and the New Republic are much closer in power than they ever had been, allowing for head-to-head combat across the stars.
Gameplay Reveal
The single-player story of Star Wars: Squadrons will help you hone your skills while taking you through a tale that shows you both sides of the war. As the Empire faces infighting and desertion after Endor, the New Republic has a classified plan to stop the mighty Imperial fleet. From mission to mission, players will switch between their custom pilots on either side; a freedom fighter for the New Republic and a hardened warrior in the Imperial Navy. Both sides are fighting for what they believe in—and both will do whatever it takes to win.
In addition to a brand-new story, you’ll also earn your wings in multiplayer battles. Dogfights is a 5v5 mode where two teams earn points by destroying opponents' starfighters in a traditional team deathmatch setting. Fleet Battles is Squadrons’ signature mode. You can play with both players (5v5) and AI (or just AI by yourself) in a multi-stage, objective-based battle. Advance the frontline by dominating the enemy in an intense tug-of-war and carry out bombing runs to take out capital ships to reach your primary objective: the destruction of the enemy flagship.
Pilots will also get to customize themselves and their ships across the fleets on both sides, both aesthetically and functionally. Neither of these will be purchasable with real-world money. Everything in-game is either earned or unlocked via gameplay.

https://preview.redd.it/9lax2dvj7r551.png?width=3840&format=png&auto=webp&s=a5a15042ce5e6e4dae51cd7ce45593ce0ed658a0
How you specialize the various functions of your favorite starfighters is even more important. While playing, you’ll be able to unlock components for your ships so that they can perform to your preferred specifications. Each starfighter can be outfitted uniquely, too, meaning an X-wing may have some different upgrade options than an A-wing or a Y-wing. Ship components range from different weaponry, auxiliary parts that aid in repairing or engaging your enemies, and much more.
Ship Component Slots
  • Primary Weapons
  • Auxiliary (x2)
  • Countermeasures
  • Hull
  • Shields
  • Engines
Each component offers unique effects to your ships, though most have a trade-off. For example, one type of shielding system will provide more protection against blaster fire but less against missiles (or vice versa). There are many more examples beyond that, too. To add to this, you can make your squadron look how you want, as well. Your two pilots (Imperial and Republic) and eight starfighters (four per side) will all have various cosmetic options that you can earn and unlock while playing. There are plenty of different ways to stand out!
Ships Available
  • T-65B X-wing starfighter
  • BTL-A4 Y-wing assault starfightebomber
  • RZ-1 A-wing interceptor
  • UT-60D U-wing starfightesupport craft
  • TIE/ln starfighter (“TIE fighter”)
  • TIE/sa bomber (“TIE bomber”)
  • TIE/in interceptor (“TIE interceptor”)
  • TIE/rp reaper attack lander (“TIE reaper”)
While customizing your ships in the hangar bay is important, how you use them in combat matters just as much! During combat, managing the performance outputs of your ship is crucial. At any given moment, you’ll be able to decide how you want your ship’s power to be channelled between your engine power (speed), laser power (offence), and shield strength (defence).

https://preview.redd.it/dv7w161m7r551.png?width=3840&format=png&auto=webp&s=b48b63bdd34dc6e29fa9bec03c9cf0731adf295a
Mastering power management on the fly is what will separate you from the space dust you leave in your wake. Not all starfighters have shields, but those that do have the ability to manually focus them entirely to the front or back when needed, giving twice the protection to one part of the ship but at the cost of no shielding to the other. With this, though, they’ll typically have slightly lower max speed and offensive capabilities than their unshielded counterparts. Additionally, unshielded ships can quickly transfer additional power to their engines or blasters when they need them the most.
Learning which ships perform best to your capabilities (while also keeping squadron’s balance in mind) will help you excel in the cockpit. Because of the uniqueness between ships and factions, you’ll have the option to have matchmaking prioritize which faction you prefer to play a part of, be it for loyalty or functionality.

https://preview.redd.it/v2rfu9zn7r551.png?width=3840&format=png&auto=webp&s=8968581d3e46265c907deab577058d6022f8ed4b
There’s even more we could get into, but we’ll save for another day. Launch isn’t far off and the team is working hard on the final polishing of the game before getting it into your hands. We’re incredibly excited for that day to come, so hang in there with us!
Keep your sights on the horizon for more news, pilots! We’d love to hear any questions you have, too! If we can, we’ll be sure to answer them in a Pilot Briefing or somewhere else online. In the future, we’re going to go deeper on some important topics, but until next time, safe travels through the hyperspace lanes! And keep your distance from any enemy ships. But don’t look like you’re trying to keep your distance. I don’t know...fly casual!
See you in the stars, pilots.
submitted by EA_Charlemagne to StarWarsSquadrons [link] [comments]

Fairy Tail: Game - Review Thread

Game Information

Game Title: Fairy Tail
Genre: Action-Adventure, Role-Playing, Fantasy
Platforms: PlayStation 4, Switch, Steam
Trailer: Reveal Trailer
Trailer: Official Gameplay Trailer
Developer: Gust Co. Ltd. Info
Publisher: Koei Tecmo
Price: Standard - $59.99 USD / £54.99 GBP / $79.99 CAD / 69,99€ EUR
Digital Deluxe - $69.99 USD / £64.99 GBP / $89.99 CAD / 79,99€ EUR
Release Date: July 30, 2020

More Information

Fairy Tail: Game FAQ

Critic Reviews

|Website/Author|Critic's Score|Quote|Platform|
|:-|:-|:-|:-|
|Nintenderos |8.5/10|Fairy Tail is the perfect adaptation to video game of the famous series of Hiro Mashima. With its strengths and weaknesses, the title is still one of Gust's most ambitious productions to date and a game that every fan of Natsu and company will enjoy.|Switch|
|WCCFTECH|6.5/10|Fairy Tail is a very similar game to the Atelier series, only one borrowing characters and story direct from another source material. The story here, based on two separate narrative arcs, works well with how it's laid out and is laid out in a way that doesn't stop newcomers to the franchise. Other aspects, however, are mixed. The turn-based combat is far more tactical than the average JRPG, offering an interesting grid-based system that helps to keep it engaging. There's a decent amount of character interaction and humour to be found within but the massive, overhanging issue is that the quests and the game in general demand far too much busywork of you in terms of building your guild, character relations, character and guild ranks and more than I care to remember. Fairy Tail has somehow managed to keep my interest but I can't deny it has too much grinding that gets boring.|Steam|
|Push Square|7/10|There's also a social element to the game as you can level up social ranks between characters once they’ve been on enough missions together, leading to unlocking new skills which can be used in battle or more bonuses for those characters. Fairy Tail carries on going even when the storyline is done; there's plenty to upgrade in the guild, and a multitude of characters to rank up, unlocking new content and cutscenes. That, combined with an enjoyable battle system, makes Gust's latest a solid experience for anime fans.|PS4|
|Cubed3|8/10|It seems as though the limited budget available for Fairy Tail has been used in the right places, saving on unimportant parts, and spending on the important bits. The gameplay, ranking and battling systems are well thought-out, and presented beautifully. For a game with such a low budget, everything has been implemented very well. It is very clear that the author of the manga, Hiro Mashima, was closely involved in developing this instalment, as it represents the feeling of the anime/manga incredibly accurately.|PS4|
|Digitally Downloaded|4.5/5|Fairy Tail is pure comfort food for people who, like me, count the JRPG as the favourite genre. It lacks the subversive intelligence of a NieR: Automata or Final Fantasy VII Remake. It also lacks the rich refinement of a Persona 5 or the epic scope of a Trails of Cold Steel. Even in comparison to Gust's own titles, it lacks the rich character development of Atelier or the sheer beauty of Blue Reflection. But Fairy Tail has one thing in spades; it's joyous, and it's the right kind of frivolous. It's a celebration of an anime that I can only assume is both silly and fun in its own right and that works as the perfect promotion for Fairy Tail: I really want to watch the anime now. Fairy Tail isn't going to be on any of my game of the year lists, but not every release needs to be pitched at those lists to be well and truly worthwhile. Fairy Tail being the game that reminded me why I loved JRPGs in the first place is more than enough.|PS4|
submitted by AstonishingSpiderMan to fairytail [link] [comments]

Thorough DD $IBIO

Who is IBIO?
  • IBIO is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health, including a virus-like particle (VLP) -based vaccine against SARS-CoV-2.
  • IBio’s subsidiary, iBio CDMO is a global leader in plant-based manufacturing. Its FastPharming and FastGlycaneering platforms provide contract development and manufacturing services via its 130,000-square foot facility in Bryan, Texas.
  • The speed and scalability of FastPharming make it an ideal choice for other innovator. companies who want to rapidly produce COVID-19 biologics.


IBIO CDMO
  • IBio is a full-service biologics CDMO equipped to take you from pre-clinical development through regulatory approval, to commercial product launch.
  • Dedicated to maintaining the effectiveness of the quality system, complying with applicable regulatory requirements and exceeding customer expectations by delivering quality products through process management and continual improvement.


CDMO SERVICES


FastPharming Technology
  • Fast. Shortens the timelines to the clinic and can move a program from gene sequence to protein production in as little as 3 weeks.

  • Economical. No Expensive, labor-intensive, and costly cell line development.

  • Quality. Production of consistent therapeutics that are well-accepted by global regulatory bodies.

  • Scalable. No time-consuming scale-up challenges.

  • Safe. Mammalian viruses can’t grow in plants; Ibio’s plant-based production platform minimizes contamination risks.
    • No animal products or animal-derived components are used at any point.
    • No Inherent adventitious agents and no competency for agent replication.

FastGlycaneering (Glycan-Engineering)
  • Demands are as high as ever for technologies that can support production of complex glycoproteins.
  • N-linked glycosylation is a critical post-translational modification to an original, naked protein that influences biological activity, protein conformation, stability, solubility, secretion, pharmacokinetics (PK), and antigenicity.
  • Can provide the power, speed and control needed to develop next-gen monoclonal antibodies, bio-betters, and fast-follower products.


Why FastGlycaneering?
  • Consistency. Ibio’s N. benthamiana expression system delivers products with inherently greater homogeneity versus traditional platforms:
    • Bacteria do not glycosylate. Yeast hyper glycosylate, and Chinese hamster ovary (CHO) cell lines do not precisely mimic human glycosylation patterns.
    • Plants do not naturally attach α1,6-fucose, terminal β1,4-galactose residues or any sialic acid residues, leading to simpler, more homogeneous N-linked glycosylation patterns.

  • Afucosylation. Desirable afucosylated G0, G1, and G2 side chains can be engineered via the removal of plant-specific sugars (core α1,3-fucose and β1,2-xylose) and the addition of terminal β1,4-galactose residues to enhance effector functions, especially antibody-dependent-cell-mediated cytotoxicity (ADCC).

  • Oligomannose Modification. FastGlycaneering enables the production of glycoproteins exclusively decorated with oligomannose residues without altering the amino acid sequence of the target protein. This can be useful for the development of lysosomal enzymes, proteins with a high clearance rate, or certain effector functions.


PIPELINE
  • IBIO-100 (Human Health)
    • Ibio’s therapeutic candidate for the treatment of systemic scleroderma, pulmonary fibrosis, and other fibrotic diseases.
    • It has been granted orphan-drug designation by the FDA for treatment of systemic sclerosis.
    • IBIO-100 is a fusion of the endostatin derived E4 antifibrotic peptide to the hinge and heavy chain of human IgG1.
    • This fusion is produced using Ibio’s proprietary FastPharming transient plant expression technology and has achieved significant reductions in fibrotic systems in both cellular and animal models.

  • IBIO-200 (Human Health)
    • A virus-like particle (VLP) based vaccine for COVID-19 disease caused by the SARS-CoV-2 strain of coronavirus.
    • VLP based vaccines are known to interact with immune cells differently than soluble antigens and can trigger both humoral and cellular responses.
    • IBIO-200 was designed to maximized uptake by antigen presenting cells in order to increase the overall immune response.
    • A SARS-CoV-2 derived antigen is fused to a self-assembling protein partner to generate the VLP.
    • The antigen is displayed in a repetitive structure and the geometry, and the particle is decorated with oligomannose molecules to resemble the structure of a naturally occurring virus.
    • FastPharming delivers a tightly controlled particle size which offers many quality and scale up advantages given that the uniform antigen display enables better dose definition and higher product yields.

  • IBIO-201 (Human Health)
    • A second SARS-CoV-2 vaccine candidate.
    • Based on a subunit platform that combines antigens derived from the SARS-CoV-2 spike protein fused with Ibio’s patented lichenase booster molecule (“LicKM”).
    • Designed to enhance immune responses.
    • Subunit vaccines have a proven track-record in protecting humans against deadly diseases, however, one of the challenges is that they often require the use of an adjuvant to boost their immunogenicity.
      • Additionally, they are often insufficiently stable to be formulated into a vaccine.
    • iBio has addressed both of these issues with the use of LicKM, a modified thermostable variant of the lichenase protein from Clostridium thermocellum.
    • LicKM fusion proteins can strengthen the initial immune response to the antigen (as measured by antibody titer) and extend the duration of the immune response, thus lowering vaccine antigen dose requirements or enabling fewer doses to establish prolonged immunity.
    • As a result, antigens fused to LicKM generally demonstrate stronger immune responses and promote long-lasting immunity.
    • Fusing the SARS-CoV-2 spike protein antigens with iBio’s LicKM technology may be advantageous in achieving prolonged immune response against COVID-19, while enabling unmatched scalability for a population-wide immunization program through FastPharming capabilities.

  • IBIO-400 (Animal Health)
    • A Classical Swine Fever Vaccine:
      • Classical Swine Fever (CSF) is a contagious, often fatal, disease affecting both feral and domesticated pigs.
      • Outbreaks in Europe, Asia, Africa, and South America have impacted animal health and food security.
      • Severe socio-economic impacts on both the pig industry worldwide and small-scale pig farming.
    • In collaboration with the Institute of Infectious Animal (IIAD) at Texas A&M University and Kansas State University.
    • Developing a safe and effective DIVA-capable subunit vaccine using FastPharming.
    • Studies have shown after single-dose vaccination, the adjuvant, plant-made CSF E2 subunit vaccine provides complete protection in challenged pigs and is accompanied by strong virus neutralization antibody responses.


Advantages of IBIO-400
  • Reduced Costs. Producing a subunit vaccine in plants saves time and money.

  • Efficacy. Studies showed protection after a single dose.

  • Safety. All vaccinated animals were protected from CSF clinical signs.

  • DIVA. Provided through the absence of Ems response.

  • Flexibility. Potential for use in bait for feral hogs (natural virus reservoirs) without substantial purification, unlike live attenuated vaccines.

  • Adaptability. Possible rapid adaptation to regional strain variations and emerging novel subgenotypes.


Partners


Team
  • Sylvain Marcel, Ph.D.
    • Vice President of Protein Expression Sciences.
    • Ph.D. in plant cell and molecular biology at the RWTH University – Fraunhofer Institute, Aachen, Germany.
    • Joined team of Dr. Barry Holtz in 2010 to develop and implement midstream manufacturing protocols during the construction and operation of the Caliber bio-therapeutics manufacturing facility.
    • Over 17 peer reviewed articles published in the field of plant biotechnology.
    • Holds one patent related to a glycan remodeling technology.
  • Brian R. Berquist, Ph.D.
    • Vice President of Downstream Process Development and Manufacturing.
    • Prior to career with iBio, Dr. Berquist was a research assistant professor in the College of Medicine at the Texas A&M Health Science Center investigating aspects of Eukaryotic DNA replication and repair.
    • Earned a doctorate in Molecular Medicine from University of Maryland School of Medicine.
    • Post-Doctoral studies in the Lab of Molecular Gerontology at the National Institute of Aging, a part of the National Institutes of Health.
    • Authored more than 25 peer-reviewed papers and book chapters.
  • Jack Owens
    • 10+ years of experience working at facilities that use plant-based transient expression systems for recombinant protein production. Experience includes:
      • Facility Design
      • Construction
      • Development of Quality Management Systems
      • Method Development
    • Owens professional experience includes work in regulated environments that are both cGMP and ISO compliant.


FINANCIALS
  • Market Cap: $658.88 million
  • Outstanding Shares: 119.8 million
  • Float: 101.8 million
  • % held by insiders: 8.78%
  • % held by institutions: 11.56%
  • Shares Short: 4.03 million
  • As of March 31, 2020, the Company’s accumulated deficit was $146.9 million.
  • For the 9 months ended March 31, 2020, the Company’s net loss was approximately $12.9 million and it had cash used in operating activities of $9.5 million.
  • On May 1, 2020, the Company paid off the total balance on the notes payable of $1,196,000.
  • As of March 31, 2020, cash on hand totaled approximately $10.0 million as compared to $4.4 million as of June 30, 2019.
  • Gross revenue for Fiscal 2020 and Fiscal 2019 were approximately $96,000 and $527,000, respectively, a decrease of approximately $431,000.
  • The decrease is primarily attributable to the timing of income earned under the strategic relationship with CC-Pharming Ltd. of Beijing, China (“CC-Pharming”) for the joint development of products and manufacturing facilities for the Chinese biopharmaceutical market, utilizing iBio’s technology. Revenue earned from CC-Pharming totaled approximately $75,000 in Fiscal 2020 versus $467,000 in Fiscal 2019. Revenue earned from other third-party customers in Fiscal 2020 totaled approximately $20,000 versus $60,000 in Fiscal 2019.


CONCERNS:
· A few very important quotes from the 10-Q filed 05/15/2020
· “To become and remain profitable, the Company must succeed in commercializing its technologies, alone or with its licensees, the service offerings provided by its CDMO facility, and in developing and eventually commercializing products that generate significant revenue. In addition, profitability will depend on continuing to attract and retain customers for the development, manufacturing and technology transfer services offered by the Company.”
· “Based on the total cash on hand of approximately $10.0 million as of March 31, 2020, combined with subsequent purchases of the Company’s common stock by Lincoln Park through the date of the filing of this report totaling approximately $10 million, we believe the Company has adequate cash on hand to support the Company’s activities for at least one year from this report date.”



CONCLUSION
I am bullish medium/long term on IBIO if they can mange to effectively license their technology platforms as well as continue to further research and develop their vaccination candidates. IF either IBIO 200 and/or 201 show positive results soon in combating SARS-CoV-2, this is could lead to government funding (possible OWS) as the ability to mass produce 500 million vaccines annually on their own is huge. They have burned through a good bit of cash and are reliant on some key factors, but overall with the direction the world is going and the increased popularity/demand for vaccines, I am positive on the future outlook of IBIO for now.
I own a position of 200 shares @ 5.29 and plan to hold until a SP of $15-20
Hope everyone enjoys and as always I invite comments, concerns, and additional information I missed. Best of luck to everyone with their trades and have a great weekend!


EDIT 1: July 29, 2020: IBIO filed an 8-K. Within the 8-K, it states "The Company plans to participate in media interviews and make a series of investor presentations over the next several weeks, during which it intends to discuss the preliminary preclinical data set forth in Exhibit 99.1, which is incorporated herein by reference." (Page 3, Item 8.01). In my opinion, you wouldn't participate in media interviews and prepare for investor presentations if you had negative preliminary data or doubts. I remain upbeat about the next few months.

submitted by ntidwell98 to EducatedInvesting [link] [comments]

Thorough DD $IBIO

Who is IBIO?
  • IBIO is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health, including a virus-like particle (VLP) -based vaccine against SARS-CoV-2.
  • IBio’s subsidiary, iBio CDMO is a global leader in plant-based manufacturing. Its FastPharming and FastGlycaneering platforms provide contract development and manufacturing services via its 130,000-square foot facility in Bryan, Texas.
  • The speed and scalability of FastPharming make it an ideal choice for other innovator. companies who want to rapidly produce COVID-19 biologics.



IBIO CDMO
  • IBio is a full-service biologics CDMO equipped to take you from pre-clinical development through regulatory approval, to commercial product launch.
  • Dedicated to maintaining the effectiveness of the quality system, complying with applicable regulatory requirements and exceeding customer expectations by delivering quality products through process management and continual improvement.


CDMO SERVICES


FastPharming Technology
  • Fast. Shortens the timelines to the clinic and can move a program from gene sequence to protein production in as little as 3 weeks.

  • Economical. No Expensive, labor-intensive, and costly cell line development.

  • Quality. Production of consistent therapeutics that are well-accepted by global regulatory bodies.

  • Scalable. No time-consuming scale-up challenges.

  • Safe. Mammalian viruses can’t grow in plants; Ibio’s plant-based production platform minimizes contamination risks.
    • No animal products or animal-derived components are used at any point.
    • No Inherent adventitious agents and no competency for agent replication.


FastGlycaneering (Glycan-Engineering)
  • Demands are as high as ever for technologies that can support production of complex glycoproteins.
  • N-linked glycosylation is a critical post-translational modification to an original, naked protein that influences biological activity, protein conformation, stability, solubility, secretion, pharmacokinetics (PK), and antigenicity.
  • Can provide the power, speed and control needed to develop next-gen monoclonal antibodies, bio-betters, and fast-follower products.


Why FastGlycaneering?
  • Consistency. Ibio’s N. benthamiana expression system delivers products with inherently greater homogeneity versus traditional platforms:
    • Bacteria do not glycosylate. Yeast hyper glycosylate, and Chinese hamster ovary (CHO) cell lines do not precisely mimic human glycosylation patterns.
    • Plants do not naturally attach α1,6-fucose, terminal β1,4-galactose residues or any sialic acid residues, leading to simpler, more homogeneous N-linked glycosylation patterns.

  • Afucosylation. Desirable afucosylated G0, G1, and G2 side chains can be engineered via the removal of plant-specific sugars (core α1,3-fucose and β1,2-xylose) and the addition of terminal β1,4-galactose residues to enhance effector functions, especially antibody-dependent-cell-mediated cytotoxicity (ADCC).

  • Oligomannose Modification. FastGlycaneering enables the production of glycoproteins exclusively decorated with oligomannose residues without altering the amino acid sequence of the target protein. This can be useful for the development of lysosomal enzymes, proteins with a high clearance rate, or certain effector functions.


PIPELINE
  • IBIO-100 (Human Health)
    • Ibio’s therapeutic candidate for the treatment of systemic scleroderma, pulmonary fibrosis, and other fibrotic diseases.
    • It has been granted orphan-drug designation by the FDA for treatment of systemic sclerosis.
    • IBIO-100 is a fusion of the endostatin derived E4 antifibrotic peptide to the hinge and heavy chain of human IgG1.
    • This fusion is produced using Ibio’s proprietary FastPharming transient plant expression technology and has achieved significant reductions in fibrotic systems in both cellular and animal models.

  • IBIO-200 (Human Health)
    • A virus-like particle (VLP) based vaccine for COVID-19 disease caused by the SARS-CoV-2 strain of coronavirus.
    • VLP based vaccines are known to interact with immune cells differently than soluble antigens and can trigger both humoral and cellular responses.
    • IBIO-200 was designed to maximized uptake by antigen presenting cells in order to increase the overall immune response.
    • A SARS-CoV-2 derived antigen is fused to a self-assembling protein partner to generate the VLP.
    • The antigen is displayed in a repetitive structure and the geometry, and the particle is decorated with oligomannose molecules to resemble the structure of a naturally occurring virus.
    • FastPharming delivers a tightly controlled particle size which offers many quality and scale up advantages given that the uniform antigen display enables better dose definition and higher product yields.

  • IBIO-201 (Human Health)
    • A second SARS-CoV-2 vaccine candidate.
    • Based on a subunit platform that combines antigens derived from the SARS-CoV-2 spike protein fused with Ibio’s patented lichenase booster molecule (“LicKM”).
    • Designed to enhance immune responses.
    • Subunit vaccines have a proven track-record in protecting humans against deadly diseases, however, one of the challenges is that they often require the use of an adjuvant to boost their immunogenicity.
      • Additionally, they are often insufficiently stable to be formulated into a vaccine.
    • iBio has addressed both of these issues with the use of LicKM, a modified thermostable variant of the lichenase protein from Clostridium thermocellum.
    • LicKM fusion proteins can strengthen the initial immune response to the antigen (as measured by antibody titer) and extend the duration of the immune response, thus lowering vaccine antigen dose requirements or enabling fewer doses to establish prolonged immunity.
    • As a result, antigens fused to LicKM generally demonstrate stronger immune responses and promote long-lasting immunity.
    • Fusing the SARS-CoV-2 spike protein antigens with iBio’s LicKM technology may be advantageous in achieving prolonged immune response against COVID-19, while enabling unmatched scalability for a population-wide immunization program through FastPharming capabilities.

  • IBIO-400 (Animal Health)
    • A Classical Swine Fever Vaccine:
      • Classical Swine Fever (CSF) is a contagious, often fatal, disease affecting both feral and domesticated pigs.
      • Outbreaks in Europe, Asia, Africa, and South America have impacted animal health and food security.
      • Severe socio-economic impacts on both the pig industry worldwide and small-scale pig farming.
    • In collaboration with the Institute of Infectious Animal (IIAD) at Texas A&M University and Kansas State University.
    • Developing a safe and effective DIVA-capable subunit vaccine using FastPharming.
    • Studies have shown after single-dose vaccination, the adjuvant, plant-made CSF E2 subunit vaccine provides complete protection in challenged pigs and is accompanied by strong virus neutralization antibody responses.



Advantages of IBIO-400
  • Reduced Costs. Producing a subunit vaccine in plants saves time and money.

  • Efficacy. Studies showed protection after a single dose.

  • Safety. All vaccinated animals were protected from CSF clinical signs.

  • DIVA. Provided through the absence of Ems response.

  • Flexibility. Potential for use in bait for feral hogs (natural virus reservoirs) without substantial purification, unlike live attenuated vaccines.

  • Adaptability. Possible rapid adaptation to regional strain variations and emerging novel subgenotypes.


Partners


Team
  • Sylvain Marcel, Ph.D.
    • Vice President of Protein Expression Sciences.
    • Ph.D. in plant cell and molecular biology at the RWTH University – Fraunhofer Institute, Aachen, Germany.
    • Joined team of Dr. Barry Holtz in 2010 to develop and implement midstream manufacturing protocols during the construction and operation of the Caliber bio-therapeutics manufacturing facility.
    • Over 17 peer reviewed articles published in the field of plant biotechnology.
    • Holds one patent related to a glycan remodeling technology.
  • Brian R. Berquist, Ph.D.
    • Vice President of Downstream Process Development and Manufacturing.
    • Prior to career with iBio, Dr. Berquist was a research assistant professor in the College of Medicine at the Texas A&M Health Science Center investigating aspects of Eukaryotic DNA replication and repair.
    • Earned a doctorate in Molecular Medicine from University of Maryland School of Medicine.
    • Post-Doctoral studies in the Lab of Molecular Gerontology at the National Institute of Aging, a part of the National Institutes of Health.
    • Authored more than 25 peer-reviewed papers and book chapters.
  • Jack Owens
    • 10+ years of experience working at facilities that use plant-based transient expression systems for recombinant protein production. Experience includes:
      • Facility Design
      • Construction
      • Development of Quality Management Systems
      • Method Development
    • Owens professional experience includes work in regulated environments that are both cGMP and ISO compliant.


FINANCIALS
  • Market Cap: $658.88 million
  • Outstanding Shares: 119.8 million
  • Float: 101.8 million
  • % held by insiders: 8.78%
  • % held by institutions: 11.56%
  • Shares Short: 4.03 million
  • As of March 31, 2020, the Company’s accumulated deficit was $146.9 million.
  • For the 9 months ended March 31, 2020, the Company’s net loss was approximately $12.9 million and it had cash used in operating activities of $9.5 million.
  • On May 1, 2020, the Company paid off the total balance on the notes payable of $1,196,000.
  • As of March 31, 2020, cash on hand totaled approximately $10.0 million as compared to $4.4 million as of June 30, 2019.
  • Gross revenue for Fiscal 2020 and Fiscal 2019 were approximately $96,000 and $527,000, respectively, a decrease of approximately $431,000.
  • The decrease is primarily attributable to the timing of income earned under the strategic relationship with CC-Pharming Ltd. of Beijing, China (“CC-Pharming”) for the joint development of products and manufacturing facilities for the Chinese biopharmaceutical market, utilizing iBio’s technology. Revenue earned from CC-Pharming totaled approximately $75,000 in Fiscal 2020 versus $467,000 in Fiscal 2019. Revenue earned from other third-party customers in Fiscal 2020 totaled approximately $20,000 versus $60,000 in Fiscal 2019.


CONCERNS:
· A few very important quotes from the 10-Q filed 05/15/2020
· “To become and remain profitable, the Company must succeed in commercializing its technologies, alone or with its licensees, the service offerings provided by its CDMO facility, and in developing and eventually commercializing products that generate significant revenue. In addition, profitability will depend on continuing to attract and retain customers for the development, manufacturing and technology transfer services offered by the Company.”
· “Based on the total cash on hand of approximately $10.0 million as of March 31, 2020, combined with subsequent purchases of the Company’s common stock by Lincoln Park through the date of the filing of this report totaling approximately $10 million, we believe the Company has adequate cash on hand to support the Company’s activities for at least one year from this report date.”

CONCLUSION
I am bullish medium/long term on IBIO if they can mange to effectively license their technology platforms as well as continue to further research and develop their vaccination candidates. IF either IBIO 200 and/or 201 show positive results soon in combating SARS-CoV-2, this is could lead to government funding (possible OWS) as the ability to mass produce 500 million vaccines annually on their own is huge. They have burned through a good bit of cash and are reliant on some key factors, but overall with the direction the world is going and the increased popularity/demand for vaccines, I am positive on the future outlook of IBIO for now.

I own a position of 200 shares @ 5.29 and plan to hold until a SP of $15-20

Hope everyone enjoys and as always I invite comments, concerns, and additional information I missed. Best of luck to everyone with their trades and have a great weekend!
submitted by ntidwell98 to pennystocks [link] [comments]

New SPACs for June

June was a busy month for SPACs. Bill (Sp)Ackman took things to the next level with the announcement of his multi-billion dollar SPAC, Pershing Square Tontine Holdings, many other players jumped in the ring. There were deals, deals, deals, with many LOIs and merger agreements dropping. Here are new SPAC S-1s for the month, happy hunting and wishing you prosperity for July!
date cik name link size (millions) symbol industry
2020-06-30 All Filings GO Acquisition Corp. S-1 500 n/a travel
2020-06-30 All Filings Deerfield Healthcare Tech Acquisition S-1 125 DFHTU health care / tech
2020-06-26 All Filings D8 Holdings Corp. S-1 250 DEH.U on global and regional consumer brands
2020-06-26 All Filings HPX Corp. S-1 200 HPX.U Brazil
2020-06-26 All Filings Malacca Straits Acquisition Co Ltd S-1 125 MLACU SE Asia
2020-06-26 All Filings dMY Technology Group, Inc. II S-1 200 DMYD.U any industry or geographic region.
2020-06-25 All Filings Artius Acquisition Inc. S-1 525 AACQU Tech, fintech
2020-06-22 All Filings Pershing Square Tontine Holdings, Ltd. S-1 3000 PSTH.U mature unicorn or private company
2020-06-15 All Filings Therapeutics Acquisition Corp. S-1 100 TXACU health/biotech
2020-06-12 All Filings PTK Acquisition Corp. S-1 100 PTK.U US Tech
2020-06-12 All Filings Panacea Acquisition Corp S-1 125 PANA.U biotech
2020-06-11 All Filings CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. S-1 200 CPSR Consumer, health, tech
2020-06-11 All Filings GS Acquisition Holdings Corp II S-1 700 GSAH.U n/a
2020-06-09 All Filings Kensington Capital Acquisition Corp. S-1 175 KCAC.U automotive
2020-06-08 All Filings Fusion Acquisition Corp. S-1 250 FUSE.U any industry or geographic region.
2020-06-01 All Filings Trebia Acquisition Corp. S-1 375 TREBU financial services, technology, software, data, analytics, services and related areas.

submitted by WesternEagle0 to SPACs [link] [comments]

Weekly, Monthly Possibilities and Catalysts

Hey guys, since we're not getting a lot of different tickers, I thought I'd make a post with some upcoming ticker catalysts and I'll give you my opinions on if I would invest and how they particularly react. I'm also going to give you my results of the last few DD's I've done, I'll actually go over that first.
PDSB - Buy - 1.88, Sell - 2.19, Current - 4.24, Month High - 4.26 YVR - Buy - 1.38, Sell - 1.45, 1.50, Current - 1.61, Month High - 1.65 CPST - Buy - 3.30, Sell - 3.35, Current - 3.33, Month High - 3.53 KDMN - Buy - 4.15, Sell - 4.10, Current - 4.14. Month High - 4.38 (ish) - Note - I actually think KDMN will run higher in the near future, but be careful. HPR - I didn't jump into this one, because one guy really insulted my DD on this. It looks like HPR is good at doing small swings, and there's an earnings coming soon if I remember right, and I think it'll spike a small amount to swing.
So I'm 3 for 4, if I were more confident I would've made bank, but I was just still beginning on my DD, so I'm happy with the results.
By the way I FINALLY got rid of XSPA, I won't talk about the loss. Lol
Current Positions - RRD - 1.22 (got in a little late, earnings soon - July 28th I think), SONN - 3.58 (got in late)
***This Stock Is To Show You What A Breakout Looks Like - CDE - Coeur Mining, Inc. - May - June has a pretty decent gap from 4-6, then it goes back down mid-late June to about 4.5-ish, and from there on you'll see quite a few supports and it just takes off to about almost 7, there's a change it may just continue to rise, but will eventually stop probably close to about 7-8, but may run through a lot of resistances. It's average volume is about 7.87 for a weeks time, while the current volume seems to be more.
Earnings coming - All of these have 0-10 Price Points with at least a 5M Volume: These are the only 2 I found worth looking at, but be cautious.
RIG - Transocean Ltd (Swiss Company) - There was a pretty decent jump early/mid June and it was halted to volatility - Earnings Date is July 29, 2020. They are a drilling / rig company and although the estimates for their earnings are likely not going to be great (still estimated better than last Q), their next estimate is assumed to be better. The biggest issue is how much better it's going to get in the near future. They have, though, positively gone from overweight to equal weight, as well as from buy to neutral. They also recently won a settlement for 185M from Eni. This is a HIGH RISK, but I would say also a high reward if you want to take a chance, currently running at 1.97, you could wait for a dip, with a price target of a reasonable 2.4 from June, so this thing will run off of good news, the last few weeks look like a swing for a few days/week.
NLY - NOT per-se a penny, but running at $7.05 price at the moment. Earnings 7/29/2020. Their earnings have been pretty consistent and making profit, with the trend estimated to be a fairly large increase from Q3-Q4 by Yahoo. Yahoo, Zacks, CNN, Wall St Analyst - Bullish Rating. Among every website I've checked has a majority vote for Buy/Bullish Rating. They were doing decent for the last 5 years between 10-12 and then COVID brought them down but they are headed in the right direction with a close price target of around $9.00 - I'd say around the next month or so. I personally might be investing in this.
I'll separate these Bio's by phases:
Phase 1: RGLS - Mid 2020's Phase 1 Trails and results presented afterwards. Bullish trend since April from $0.48 - $1.02 Currently. There's technically been a breakout due to a pennant trend but that doesn't mean it's not going to continue to go up. This is all subjective to how well the Phase 1 goes. Play this with caution. RGLS has almost all Bullish/Buy/Hold and from what I've seen no sell/bearish recommendations. Price target around $1.25 realistically.
Phase 2: SAVA - This is their current FDA status, Phase 2b trial did not meet primary endpoint - May 15, 2020. Detailed data due 3Q 2020. This isn't a great sign, but they recently had a good catalyst with their presentation for their SAVADX at Biomarkers for Alzheimers Disease Summit, they're trending upwards, overall from May. There's mostly holds, long holds recommendations and I think one or two sells/bullish trends. Invest in this one slowly, and be sure to pay very close attention to their trials/status. I will be having this one on my radar.
Phase 3: ACST - Current FDA Status, Phase 3 TRILOGY 1 data did not meet primary endpoint - January 13, 2020. TRILOGY 2 data due 3Q 2020. Against, not great news, but end of Q3 is closer to September, so if you want to buy early, between now and August will be the time. They deal with high blood levels of triglycerides. This stock seems to have a lot of volatility, but has a cup and handle from Feb till June, and may look like they're running the same trend possibly till Sept. I'm not huge on this, but may throw a small position as we get closer, near the "bottom" of the cup.
The rest of these are withing the PDUFA Phase: TRVN - August 7, 2020 - Almost every site I've seen has a bullish, buy trend, no sell suggestions. Price target approximately $3.5 - $4.0 which doesn't seem so absurd. Oliceridine (TRV130) Moderate to severe acute pain. April - Now from 0.50 - 2.05 now, constant positive trend.
ETON - August 10, 2020 - FDA status - Allergic conjunctivitis - CRL issued July 12, 2019. NDA resubmitted with new PDUFA date of August 10, 2020. Although positive trend, it's a little less of a trend that TRVN. It's a split between a few sells, a few buys, and a few holds. More buys, followed by sells, then holds. Price target around 12-15, which I think is a little much, so I'd say closer to 7-10 if they are positive in their medicine.
LPCN - August 28, 2020 - TLANDO - LPCN 1021 Men with low testosterone (Low T) - Similar trend as TRVN, price target of $2.5-$3.0. Most all buys, 1-2 holds, no sells.
MNK - PDUFA date September 12, 2020. Advisory Committee Meeting July 15, 2020 voted 8-7 that the benefits outweigh the risks. I'd stay away from this one, I was already in the process of writing this, so I'll just finish off with it going bearish, you could do a few swings, but I wouldn't risk it. More sells, then holds, then a few buys, but minimally.
AQST - September 27, 2020 - Bullish trends currently, but this one is tricky. The medicine itself seems to have quite a few issues/downsides, although it seems the positives outweigh the negatives, Epileptic seizures. Earnings will be August 4th, if you can get in fairly low, you can probably swing this a little since it's ran up a little already. Earnings isn't expected to be good, so you could swing this dip and wait till PDUFA on the 27th, possibly even swing a few times in between. Almost all buys, 1-2 holds, either 1 or no sells. Ridiculous PT of around 15-18. I'd say a more reasonable would be 6.5-9.
Hope you guys like this, and hope this helps. I'd do more but I'm tired.
submitted by megatran2000 to pennystocks [link] [comments]

Wrestling Observer Rewind ★ January 18, 1988

Going through old issues of the Wrestling Observer Newsletter and posting highlights in my own words, continuing in the footsteps of daprice82. For anyone interested, I highly recommend signing up for the actual site at f4wonline and checking out the full archives.
• PREVIOUS •
1987
FUTURE YEARS ARCHIVE:
The Complete Observer Rewind Archive by daprice82
1-4-1988 1-11-1988
  • The Main Event (still yet to be named) is officially on for February 5. It’ll be live for an hour from Market Square Arena in Indianapolis. Hogan defends the title against Andre and Savage challenges Honkeytonk Man for the Intercontinental Title, while the Harts face Strike Force for the Tag Titles. Dave anticipates massive ratings, given the speculation that Andre will win the title. He expects this to be the most-watched show in U.S. wrestling history. It should set things up for Wrestlemania, and given that Dave doesn’t see Hogan pinning Andre or it would kill interest in any Hogan match for Wrestlemania. They need a good finish to keep the match looking good and be flukey so Hogan’s rematch interest will be high. Dave has no idea how exactly right he is about that aspect of the match. Hogan kicks out and the referee counts three anyway, then we learn that there was twin magic by the Hebners, as Ventura and McMahon declare that Dave and Earl Hebner look like identical twins. They sure do, as long as identical means one looks about 40 lbs heavier and ten years older than the other.
Watch: Early, but here’s the Hogan Andre match
  • Royal Rumble vs. Bunkhouse Stampede Finals is the next battle to get through, though. A Hogan vs. Andre debate is to headline the show, along with Steamboat vs. Rude, Dino Bravo’s attempt to bench press 700 lbs, and the Jumping Bomb Angels vs. Glamour Girls in a best 2 of 3 falls match (Dave expects a title change). Crockett’s show will be their first national pay-per-view and the lineup includes a weak undercard. The bunkhouse finals is headlining, but you have Flair vs. Hawk for the NWA Title, Windham vs. Zbyszko for the Western States Title, Sting vs. Rotunda, and more. What’s clear is that they’ll be available in much fewer homes than Survivor Series was, and it’s questionable how well they’re going to do at the live gate too. Dave’s planning to host a viewing party for both shows in the Bay Area. He notes how silly it is that the better show on paper is being offered for free.
  • The big news of the week is WWF signing Big Bubba Rogers. His salary with JCP didn’t give him a set salary for the year due to a different structure to his contract from everybody else, so although he was under contract, WWF apparently feels confident about any potential legal battle. At first Dave thought this would be a bigger deal, since it would be a challenge to the legality of Crockett’s contracts, but it’s just a guy jumping ship.
  • An interesting lawsuit was decided this past week. In Binghamton, New York on October 28, 1986, Randy Savage “injured” Ricky Steamboat (this was Savage crushing Steamboat’s larynx with the ring bell). Anyway, a $1.15 million lawsuit resulted, as members of the local volunteer EMT squad claimed that Steamboat “violently struck” one of them and seriously hurt her. They were on standby on authorization by WWF with orders to only be called if someone was injured. Well, a WWF employee told the squad that Steamboat was “seriously injured,” they went to help, and then the incident happened. The lawsuit alleges that the damage from Steamboat’s strike caused injury to her ribs, sternum, chest, and back sufficient to leave her disabled. WWF is also being sued because one of their broadcasters (allegedly Bruno), said “Incompetency on the part of those paramedics, there, don’t you agree,” which the suit alleges that Bruno was declaring them all unfit to practice their profession. They also contended that the injured EMT was broadcast on tv illegally. WWF settled out of court, and both sides are quiet about how much the payout was. Dave checked back with his copy of the tape and with a friend’s, and he can’t make anything out enough to say one way or the other, but his friend says it was Ventura and not Bruno who made the comment.
Watch: Randy Savage "injures" Ricky Steamboat
  • Dave expects the Penthouse story on the Von Erichs to lead to a lawsuit. Dave’s read an advance copy of the story and it’s well-written, but it could make some waves and Dave’s gut says Fritz may sue over it. Spoilers - the article isn’t going to run in the May issue but instead be pushed back yet again to October. I’ll include it when we get there, but if you’re itching to read it now, it’s the “Born Against Bashing” article.
  • [Memphis] Nobody’s turned heel between Jerry Lawler and Bill Dundee yet. Given this week’s happenings, a Dundee turn should be expected soon. They had a match on January 4 where Dundee hit Lawler with a chain to get the pin, only for the decision to be reversed and Lawler got to keep the diamond ring he put up against Dundee’s $5000 check (which Dundee stopped the payment on). So they’ll rematch again with the $5000 in cash vs. the ring. The crowd cheers them both, neither has made a hard turn, and both are doing promos that are slightly more heel-leaning. It’s a really interesting confluence of factors here.
  • Terry Taylor, who just on Sunday went over on the WTBS show for Crockett, appears to have jumped ship to Memphis. Surprise to Dave and probably a surprise to Crockett.
  • [Memphis] Dave hears Shawn Michaels is such a good heel because it’s not an act.
  • Crockett’s tv this week is hinting that Barry Windham will be the next Horseman. Dave’s not sure how much sense it makes to turn Windham given his program with Steve Williams.
  • [NWA] Jim Cornette is now managing Dick Murdoch.
  • [NWA] Thunderfoot #1 got fired, and there’s a bigger story beneath that. He was given notice on Christmas day, and after he got his notice and was driving home, he allegedly ran a red light and hit another car, killing the other driver. He was arrested on January 3 on charges of vehicular manslaughter, possession of drug paraphernalia, and passing bad checks. He faces up to five years in prison if he’s convicted.
  • Speaking of legal news, the grand jury in Tennessee couldn’t find enough evidence to indict Rocky Johnson on the rape allegation. They felt that the girl’s story didn’t hold up to scrutiny and declined to indict him.
  • WCCW is still riding Fritz’s collapse at Christmas. They’re continuing to emphasize that things are not going well for him while making clear that he’s not going to die. Talking out both sides of their mouths, really, as they try to ride the line between good and bad taste.
  • According to an inside source, Ken Mantell owns half of WCCW while Kevin and Kerry each own a quarter. Fritz may not own anything anymore, but he obviously has sway.
  • WCCW managed to sell out the Sportatorium on January 2. It was the first ever Saturday night show they’ve done there. Tickets were $5 no matter the seats, and beer was 50 cents, and they had to turn away a thousand people because of the sellout. Two days later in Fort Worth they drew 350 fans.
  • Global Wrestling Alliance, the one that’s publicly traded, started television syndication this past weekend. The show they aired was taped six months ago, though, so guys like Bugsy McGraw and Cyclone Negro (whom they billed as world champion) probably aren’t involved anymore. Nevertheless, they’re said to have the best production values of any independent promotion, but the wrestling wasn’t great.
  • Badnews Allen is leaving Stampede for WWF. He’s already made his tv debut there, even, as Badnews Brown, which just has Dave puzzled over why they turned Steve DiSalvo if Allen’s leaving.
  • Terry Gordy, Stan Hansen, and the Malenko brothers will be headlining the next All Japan tour starting in late February.
  • Curt Hennig’s tour in All Japan as AWA champion is being received poorly. Weekly Pro Wrestling called his debut match with Tiger Mask II the “worst AWA title match ever in Japan” (he lost the match by countout too) and he had a double countout with John Tenta (who is solidly mid-level). He pinned Kawada on January 4. This is all very confusing to Dave because Hennig is the only world champion from the States who’s touring Japan, and they book him like this? Flair’s not coming back, it looks like, and Hogan hasn’t come to Japan since 1985. Williams’ UWF title doesn’t count anymore and isn’t recognized when he tours New Japan. Dave hasn’t seen the match with Tiger Mask, but those who have tell him it’s probably a style mismatch that led to it being no good. This kind of coverage is going to make it really hard for Hennig to get over in Japan.
  • All Japan Women is now hitting the highest ratings of any promotion in Japan. Their last two shows clocked 11.3 ratings. All Japan is generally in the same ballpark when it’s on prime-time on Saturdays, but only pulls a 6-7 in the afternoon. New Japan’s prime time ratings have been around the 8 mark. Devil Masami’s retirement show (which Dave covered in the big issue on his trip to Japan at the end of 1987) is part of the last episode they aired, and it’s expected to handily top the previous two episodes.
  • New Japan’s December 27 show ended in a riot, but pulled half a million at the gate to a sellout crowd of 11,090. The riot began during Choshu and Saito vs. Fujinami * Kimura, and picked up a few times before the show was over (Vader squashing Inoki in under three minutes was the main event). The crowd tore the building up over the course of an hour and almost set the place on fire, which has led to Sumo Hall banning New Japan. Their tv spot will also be moved to Mondays at midnight once baseball season starts. Dave saw a newspaper clipping from during the Choshu tag match and you can tell the crowd is almost out of control already. A similar riot happened in 1984 at the old Sumo Hall after a Hogan/Inoki match where Choshu lariated Hogan and Inoki, and Inoki wound up beating the countout). Another similar riot took place on March 26, 187 at Castle Hall in Osaka after an Inoki/Saito draw.
  • New Japan’s way of dealing with their recent problems is to organize a junior heavyweight tournament. This will be the biggest tournament of its sort since 1984, which had dynamite Kid, Davey Boy Smith, Takada, Black Tiger, Bret Hart, and others. This year’s tournament has Owen Hart, Keiichi Yamada, Koshinaka, Takada, Hiroshi Hase, Hiro Saito, and more. They opened the tournament on their January 4 show, and on that card in a tag team match was Steve Blackman. And that’s his Observer Rewind debut.
  • Continental (Alabama) had Wendell Cooley beat Dutch Mantell on their January 4 show. If Cooley lost, he would have had to leave the territory, and Mantell losing means Cooley gets his contract back. They went with the story that Mantell owned Cooley’s contract, which meant Mantell was even collecting his earnings, which meant Cooley didn’t have money to buy his kids gifts. They even showed Cooley’s daughters with an empty Christmas tree.
  • Tom Zenk has settled his legal troubles with WWF and signed with AWA. Giant Baba wants to feature Zenk heavily, but feels he needs to be a big star in the U.S. before he comes to Japan, hence the AWA move. As far as his legal issues, WWF sued Zenk for breach of contract, and they settled out of court. Zenk will have to give WWF a percentage of his earnings in 1988 rather than the $70,000 WWF initially sued for. Dave likens the situation to if WWF tried to sign a Crockett guy on a guaranteed contract - if Crockett just let the guy go, it’d open the door up for WWF to poach anyone. Terry Taylor was actually on a similar deal, actually, with Crockett, but Crockett seems plenty happy to let him go to Memphis.
  • Blackjack Mulligan beat the shit out of Bob Roop backstage at an independent show on December 29. Apparently there’s some personal issues dating back to Roop’s time booking Florida.
  • One of the letters this week wonders if it’s wise for the Road Warriors to call themselves Neo-Nazis if they’re faces. In a promo on a recent episode of World Wide they twice called themselves Neo-Nazis, and the writer wonders if that should maybe be something faces don’t call themselves but which should be reserved for heels. Dave doesn’t touch this part of the letter and instead answers the part of the letter about whether WWF should bring back Bruno Sammartino and Pedro Morales. Dave’s verdict is that WWF shouldn’t live in the past.
  • Badnews Brown debuted at the WWF tv tapings on January 5 after an untaped opening match. He came out and beat up Sam Houston. He made his tv debut during the third hour of the tapings.
Watch: Badnews Brown's WWF debut
  • Hogan and Savage are working better together than Hogan and Piper did because, Dave’s told, Savage knows his place. When they beat the Hart Foundation and Honkytonk Man at the end of the weekend’s tapings, Savage and Liz stayed in the background as Hogan posed. Piper always butted heads with Hogan because both wanted to be the central star, while Savage knows he’s the number two guy.
  • Paul Orndorff is basically retired to go into the bowling business. He just no-showed a bunch of shows, leaving Rick Rude to try and carry Ultimate Warrior on house shows.
  • King Kong Bundy’s ads for Head Start Computers are going real well. The company wants to bring him on for conventions and appearances full-time.
THURSDAY: Forecast for The Main Event, Bunkhouse Stampede looking to fail, major retirements coming for AJW, and more!
submitted by SaintRidley to SquaredCircle [link] [comments]

An in-depth analysis of the Oregon State Football Program based on how cool their logo is

A couple days ago, someone made a post asking why the Oregon State football program has struggled in recent years, which made me remember that Oregon State had some solid years when I was growing up. Moreover, I always thought their uniforms were cool when I was younger. Thus, I wondered if there was a correlation between how cool Oregon State's logo was to their play on the field. The correlation is a much stronger than one may think.
According to sportslogohistory.net and most other sites, Oregon State has had 3 main logos in its school history. The first one was used until 1996, but its introduction date is unknown. Any retro Oregon State gear used this logo, dating all the way back to a pennant claimed to be made in the 1940s. I'm not sure if beaver racism is a thing, but I feel like this logo is slightly beaver racist. Perhaps it's the buck teeth being a little too big for my liking; Buc-ee's has a much better teeth-to-cartoonish-grin ratio. As the years went on, it seems that the logo dropped some of the detail, which adds to its cartoony appeal, and the sailor hat is objectively cool. Thus, this logo is the second coolest logo in Oregon State history. And it turns out it accompanied the second best era in Oregon State football. If the logo was already in use by the 1940s, it could have been seen alongside head coach Tommy Prothro's successful Beaver teams of the late 50s and early 60s. Prothro won the PCC in '56 and '57, and then the Athletic Association of Western Universities in 1964. They also played in two Rose Bowls under Prothro, and won the Liberty Bowl in '62. However, they wouldn't even appear in a bowl game after the '64 Rose Bowl for another 35 years. Obviously, it was time for a change.
In 1997, Oregon State introduced the logo that many of us grew up with. To put it in a scholarly manner, it looked badass. The beaver does look a little more frightened than I remember. However, it's less of a "I'm going to run away" kind of fear, and more of a "if you take one step towards me, I will sneak into your house in the middle of the night and gnaw your leg off with my own buck teeth" kind of fear. Pair it with a slick all black uniform set, and this Oregon State team looked primed for success. And they indeed were successful. After using this logo and uniform scheme for 2 years, Oregon State made their first bowl game in 37 years under Dennis Erickson. Two years later, they would win the Fiesta Bowl. After Erickson left for an NFL job, Mike Riley would lead the Beavers to 5 more bowl victories during the 2000s. In the last year of this logo's life, the Beavers made a respectable bowl game in the Alamo Bowl, losing to one of Mack Brown's last Longhorn teams, who ended the season ranked. This was by far the best era in Oregon State's history, and was accompanied by its coolest logo.
Then, in 2013, the Oregon State athletic department decided that they were fed up with winning and looking cool while doing it, and changed the logo to the one used today. This beaver looks like it's unsure of where it is, and how it got there. It looks like it would attend a seminar on why the older logo displayed beaver racism and then would write his American Studies midterm he totally forgot existed the night before it was due, because he just isn't aware of anything. The new beaver would be accompanied by new uniforms that looked like the ones you half-assed in Madden 2007's uniform creator feature. Oregon State's on field success mirrored these design changes. After making a bowl game in 2013 with players recruited using the older logo, the Beavers have failed to make another bowl game. It would not surprise me in the slightest that Mike Riley left solely because of how disappointed he was in the beaver redesign. And how was Gary Anderson supposed to recruit, strategize, or do anything successful with a team sporting such a lame looking beaver? Easily the lamest logo, and a lack of success has followed alongside it.
Conclusion: Oregon State's success on the field has a strong correlation with how cool its beaver logo looks. If I were a part of the Oregon State athletic department, I would immediately invest in a redesign. Perhaps a simple switch back to the scheme used from 1997 - 2012, or combining that logo with the cartoony appeal of the older sailor logo. Regardless, if Oregon State wants to become a threat to win the PAC-12 title in the playoff era, it must switch to a cooler beaver logo.
submitted by Not_The_Olive_Garden to CFB [link] [comments]

Full list of upcoming games on the Nintendo Switch (US) (Updated 6/20/2020)

Console exclusives (games that are also on PC and/or mobile, but not on other consoles) in Italics. Nintendo exclusives (games that are only on Nintendo platforms) in bold.
For those looking at this list and not sure what's likely to be noteworthy, I have compiled a page with the noteworthy releases on Switch for June 2020. Please give it a look if you want to see what games are likely to be some of June's highlights! I have updated this list to include new announcements, as well as to show Metacritic scores of released games that were on the list.
As for the full list, here you go:
Games Release date Date confirmed by?
A Summer With the Shiba Inu 6/26/20 Nintendo.com
City Driving Simulator 6/26/20 Nintendo.com
Sudoky 6/26/20 Nintendo.com
Yes, Your Grace 6/26/20 Nintendo.com
Quell Zen 6/27/20 Nintendo.com
Mozart Requiem 6/30/20 Official Website
No Straight Roads 6/30/20 Official Trailer
The Legend of Heroes: Trails of Cold Steel III 6/30/20 Nintendo.com
The StoryTale 6/30/20 Nintendo.com
Dog Duty Spring 2020 Official Twitter Post
Fury Roads Survivor Spring 2020 Official Website
Ghost of a Tale Spring 2020 Nintendo.com
Refractor Spring 2020 Kinda Funny Games E3 Showcase
Terror Squid Spring 2020 Official Website
Wingspan Spring 2020 Nintendo.com
Alter Cosmos Q2 2020 Official Website
Driftland: The Magic Revival Q2 2020 Official Website
Slice of Life Q2 2020 Official Twitter Post
The Red Lantern Q2 2020 Nintendo.com
Train Mechanic Simulator Q2 2020 Official Website
Hellpoint Before the end of Q2 2020 Official Trailer / Official Twitter Post
Dreamscaper (Timed Exclusive) Early 2020 Nintendo.com
Eastward Early 2020 Nintendo.com
Phogs! Early 2020 Indie World Showcase 8.19.2019
Windjammers 2 Early 2020 Official Trailer
Sports Story Mid 2020 Nintendo.com
My Bewitching Perfume 7/1/20 Nintendo.com
Biped 7/2/20 Nintendo.com
Caretaker 7/2/20 Nintendo.com
Couch Co-Op Bundle Vol. 2 7/2/20 Nintendo.com
Digerati Indie Bundle Vol. 3 7/2/20 Nintendo.com
Infliction: Extended Cut 7/2/20 Nintendo.com
Pool Slide Story 7/2/20 Nintendo.com
The Otterman Empire 7/2/20 Nintendo.com
Clash Force 7/3/20 Nintendo.com
Ghost Grab 3000 7/3/20 Nintendo.com
Infini 7/3/20 Nintendo.com
Singled Out 7/3/20 Nintendo.com
Gerty 7/6/20 Nintendo.com
Catherine: Full Body 7/7/20 Nintendo.com
Escape Game Fort Boyard 7/7/20 Nintendo.com
Superliminal 7/7/20 Nintendo.com
CrossCode 7/9/20 Nintendo.com
Demon's Rise - War for the Deep 7/9/20 Nintendo.com
Elden: Path of the Forgotten 7/9/20 Nintendo.com
TroubleDays 7/9/20 Nintendo.com
Bloodstained: Curse of the Moon 2 7/10/20 Nintendo.com
Deadly Premonition 2: A Blessing in Disguise 7/10/20 Nintendo.com
The Great Perhaps 7/10/20 Nintendo.com
Story of Seasons: Friends of Mineral Town (AKA Harvest Moon: Friends of Mineral Town) 7/14/20 Nintendo.com
Neon Abyss 7/14/20 Official Trailer
void tRrLM(); //Void Terrarium 7/14/20 Nintendo.com
Aeolis Tournament 7/16/20 Official Website
Bounty Battle 7/16/20 Official Twitter Post
Radical Rabbit Stew 7/16/20 Official Twitter Post
We Should Talk 7/16/20 Nintendo.com
Paper Mario: The Origami King 7/17/20 Nintendo.com
Warhammer 40,000: Mechanicus 7/17/20 Official Gameplay Demo (IGN Summer of Gaming 2020 Event)
Rock of Ages 3: Make & Break 7/21/20 Official Twitter Post
Megadimension Neptunia VII 7/28/20 Nintendo.com
Samurai Shodown Neogeo Collection 7/28/20 Official Website
Locomotion 7/30/20 Nintendo.com
Castlestorm 2 7/31/20 Official Trailer (IGN Summer of Gaming Event 2020)
Fairy Tail 7/31/20 Nintendo.com
Bossgard July 2020 Official Twitter Comment
Bullet Age July 2020 Nintendo.com
Drive Buy July 2020 Official Trailer
RetroMania Wrestling July 2020 Official Twitter Post
Umihara Kawase Bazooka! July 2020 Official Trailer
Skully 8/4/20 Nintendo.com
West of Dead 8/5/20 Official Trailer
PGA Tour 2K21 8/21/20 Official Twitter Post
Remothered: Broken Porcelain 8/25/20 Official Trailer (GamesRadar's Future Games Show 2020)
Final Fantasy Crystal Chronicles Remastered Edition 8/27/20 Official Trailer
Captain Tsubasa: Rise of the New Champions 8/28/20 Official Trailer
Giraffe and Annika 8/28/20 Official Trailer
Immortal Realms: Vampire Wars 8/28/20 Official "Dev Diary" Trailer
Jump Force Deluxe Edition 8/28/20 Official Trailer
Windbound 8/28/20 Official Twitter Post
Collar X Malice -Unlimited- August 2020 Official Website
Spinch 9/3/20 Official Trailer
AVICII Invector 9/8/20 Nintendo.com
This is the Zodiac Speaking 9/24/20 Official Twitter Post
Port Royale 4 9/25/20 Official Twitter Post
TrollHunters: Defenders of Arcadia 9/25/20 Official Trailer
Sunless Skies: Sovereign Edition August/September 2020 Official Twitter Post
Curved Space September 2020 Official Trailer
Space Crew September 2020 Official Trailer
Tin & Kuna September 2020 Official Website
Alwa's Legacy Summer 2020 Official Twitter Post
Aokana - Four Rhythms Across the Blue Summer 2020 Official Twitter Post
Bake 'N Switch Summer 2020 Nintendo.com
Baldo: The Guardian Owls (Timed Exclusive) Summer 2020 Nintendo.com
Calico Summer 2020 Official Website
Carrion Summer 2020 Official Trailer
Cyanide and Happiness: Freakpocalypse: Part 1 (Timed Console Exclusive) Summer 2020 Nintendo.com
Eldest Souls (Timed Console Exclusive) Summer 2020 Nintendo.com
GERRRMS Summer 2020 Nintendo.com
Hotshot Racing Summer 2020 Official Trailer (GamesRadar's Future Games Show 2020)
House Flipper Summer 2020 Official Trailer
Inertial Drift Summer 2020 Official Twitter Post
King of Fighters R-2 Summer 2020 Official Trailer
King of the Hat Summer 2020 Nintendo.com
PixelJunk Eden 2 Summer 2020 Nintendo.com
Rivals of Aether: Definitive Edition Summer 2020 Official Trailer
Rogue Heroes: Ruins of Tasos Summer 2020 Official Website
Samurai Jack: Battle Through Time Summer 2020 Official Trailer (exclusively released through IGN)
Samurai Shodown! 2 Summer 2020 Official Website
Sky: Children of the Night Summer 2020 Nintendo.com
Street Power Soccer (AKA Street Power Football) Summer 2020 Official Twitter Post
The Last Campfire Summer 2020 Nintendo.com
Volta-X Summer 2020 Official Trailer (Gamespot Exclusive)
Counter Terrorist Agency Q3 2020 Official Website
Dungeon Defenders Awakened (Timed Exclusive) Q3 2020 Official Twitter Post
Going Under Q3 2020 Official Trailer
Lord Winklebottom Investigates Q3 2020 Official Website
Nogunz: Doppelganger Edition Q3 2020 Official Trailer
The Academy: The First Riddle Q3 2020 Official Trailer
Prinny 1•2: Exploded and Reloaded 10/13/20 Official Trailer
Robotics;Notes Double Pack 10/13/20 Official Trailer
Transformers: Battlegrounds 10/13/20 Official Trailer
Dusk Halloween 2020 Official Trailer
Maid of Sker October 2020 Official Twitter Post
Nickelodeon Kart Racers 2 October 2020 Official Trailer (IGN Summer of Gaming Event 2020)
Piofore: Fated Memories October 2020 Official Website
XIII 11/10/20 Official Trailer (IGN Summer of Gaming Event 2020)
Cris Tales 11/17/20 Official Webpage
Cafe Enchante November 2020 Official Website
Ruggero Deodato's Cannibal November 2020 Official Website
Pretty Princess Party December 2020 Official Website
Apex Legends Fall 2020 Nintendo Twitter Post
Axiom Verge 2 Fall 2020 Indie World Showcase 12.10.2019
Commandos 2 HD Remaster Fall 2020 Official Website
Cyber Shadow Fall 2020 Official Website
Empire of Sin Fall 2020 Nintendo.com/Official Twitter Page
Harvest Moon: One World Autumn 2020 (European Release Date) Nintendo.co.uk
Toy Soldiers HD Autumn 2020 Official Website
Fuser Fall 2020 Nintendo.com
Circadian City Q4 2020 Announce Trailer
Defense Corp Q4 2020 Developer Comment on Reddit
Pumpkin Jack Q4 2020 Official Trailer
Clive 'N' Wrench Winter 2020 Official Trailer
B.Ark (Timed Exclusive) Late 2020 Nintendo.com
Beach Buggy Racing 2 Late 2020 Official Website
Dicey Dungeons Late 2020 Nintendo.com
Hoa Late 2020 Wholesome Direct 5-26-2020
Quantum League Late 2020 Nintendo.com
Signs of the Sojourner Late 2020 Official Trailer
Dangerous Driving 2 Holiday 2020 Official Website
Re:Zero – The Prophecy of the Throne Winter 2020/2021 Official Trailer
Ageless 2020 Official Twitter Post
Aground 2020 Official Website
Ary and the Secret of Seasons 2020 Official Webpage
Astrodogs 2020 Developer post on Reddit
Black Book 2020 Official Trailer
Boyfriend Dungeon 2020 Nintendo.com
Bravely Default II 2020 Nintendo.com
Breakpoint 2020 Official Twitter Post
Car Mechanic Flipper 2020 Official Website
Circuit Superstars 2020 Official Website
Cloudpunk 2020 Official Developer Post on Reddit
Cthulhu: Books of Ancients 2020 Official Website
Devil's Hunt 2020 Official Twitter Post
Dex 2020 QubicGames 2020 Direct
Digimon Survive 2020 Anime Expo panel (relayed by NintendoEverything.com)
Door Kickers 2020 QubicGames 2020 Direct
Electrix 2020 Official Website
Faeria 2020 Nintendo.com
Farm & Fix 2020 2020 Official Website
Farm Manager 2018 2020 Official Website
Flipper Mechanic 2020 Official Website
Gearshifters 2020 Official Website
Gleamlight 2020 Nintendo.com
God Fire 2020 QubicGames 2020 Direct
Good Night Knight 2020 QubicGames 2020 Direct
Greak: Memories of Azur 2020 Official Trailer
Hatch Tales (Formerly Chicken Wiggle Workshop) 2020 Official Website
Haven 2020 Official Website
Hazel Sky 2020 Official Trailer
Heart of the Woods 2020 Official Website
Heaven's Vault 2020 Official Twitter Post
Helheim Hassle 2020 Official Trailer
Hero: Flood Rescue 2020 Official Website
Hindsight 20/20 2020 Announce Trailer
Hyperbrawl Tournament 2020 Official Website
I Am Dead (Timed Exclusive) 2020 Nintendo.com
Inmost 2020 Nintendo.com
Is It Wrong to Try to Pick Up Girls in a Dungeon? Infinite Combate 2020 Official Trailer
Kingdom Hearts: Melody of Memory 2020 Official Japanese Trailer (lists worldwide release)
Kingpin: Reloaded 2020 Official Trailer
King's Bounty II 2020 Nintendo.com
Lego Star Wars: The Skywalker Saga 2020 Announce Trailer
Little Nightmares II 2020 Announce Trailer
Littlewood 2020 Official Twitter Page
Lords of Exile 2020 Official Website/Official Trailer
Mail Mole 2020 Official Trailer
Maneater 2020 Official Twitter Post
Mars Horizon 2020 Official Website
Metamorphosis 2020 Official Trailer
Mineko's Night Market 2020 Nintendo.com
Moero Crystal H 2020 Official Trailer
Moon Village 2020 Official Website
Mushrooms: Forest Walker 2020 Official Website
N1RV Ann-A 2020 Announce Trailer
Necrobarista 2020 Official Twitter Page
No More Heroes 3 2020 Nintendo.com
Nyx: The Awakening 2020 Official Reveal Teaser/Official Website
Olympic Games Tokyo 2020 - The Official Videogame 2020 Official Website
P.U.G.S. Agents 2020 Official Website
Pillars of Eternity II: Deadfire 2020 Interview With Developer
Plastic Rebellion 2020 Official Website
Real Boxing 2 2020 QubicGames 2020 Direct
Robotics;Notes Elite 2020 Official Website
Rogue Company 2020 Nintendo.com
Scourge Bringer 2020 Nintendo.com
Sail Forth 2020 Nintendo.com
Sakuna: Of Rice and Ruin 2020 Official Website
Samurai Gunn 2 2020 Nintendo.com
Shiren the Wanderer: The Tower of Fortune and the Dice of Fate 2020 Official Trailer
Spacebase Startopia 2020 Announce Trailer
Spin Rhythm XD 2020 Announce Trailer
Spiritfarer 2020 Nintendo.com
Spitlings 2020 Official Twitter Page
The Good Life 2020 Nintendo.com
The Survivalists 2020 Nintendo.com
This Is Pool 2020 Official Website
This Is Snooker 2020 Official Website
Those Who Remain 2020 Official Twitter Page
Trigger Witch 2020 Kinda Funny Games E3 Showcase
Unlucky Seven 2020 Official Website
Unto the End 2020 Official Trailer
Vampire: The Masquerade - Shadows of New York 2020 Official Steam Page
Zengeon 2020 Official Trailer
Purrtato Tail: By the Light of the Elderstar 2020 "or when it's done" Official Fact Sheet
Gods & Monsters Fiscal 2020-2021 (Between April 1 2020 and April 1 2021) E3 Trailer/Official Announcement
House Designer 2020/2021 Official Website
Ring of Life: Survive in Proxima 2020/2021 Official Website
Wrath: Aeon of Ruin 2/25/21 Official Website
Blue Fire (Timed Exclusive) Q1 2021 Nintendo.com
Foreclosed Q2 2021 Developer Interview
Backbone 2021 Official Website
Dordogne 2021 Official Trailer
Fallen Legion: Revenants 2021 Official Trailer (New Games Plus Expo 2020)
Lost in Random 2021 Official Press Release
Lost Words 2021 Official Twitter Post
Rogue Lords 2021 Official Trailer
Serial Cleaners 2021 Official Trailer
Skatebird 2021 Indie World Showcase 12.10.2019/Official Statement on Kickstarter.com
Starbase Startopia 2021 Official Twitter Post
Summer at the Edge of the Universe 2021 Official Twitter Post
Trails of Cold Steel IV 2021 Official Trailer
Ys IX: Monstrum Nox 2021 Official Trailer (New Game Plus Expo 2020)
Sea of Stars 2022 Official Trailer/Official Trailer
(Note: TBA Dates and Missed Release Dates in comments)
I miss anything? Mis-marked exclusivity? Have an official source with updated info? Let me know!
submitted by CaspianX2 to NintendoSwitch [link] [comments]

HCAC DD

HCAC DD
HCAC - Hennessy Capital Acquisition Corp. IV
Thought I would share my DD with the community. Take it or leave it. Knowledge/insight and bear cases are very welcome. Cheers!
Key Takeaways:
· Sept 3rd Deadline fast approaching
· 72% institution owned (JP Morgan, BMO, BOA, Deutsche Bank, Goldman, Morgan Stanley)
· 100 percent still in trust @ 300m
· VERY solid leadership (this is the groups 4th SPAC - their first Bluebird was very successful)
· Blackrock doesn’t fuck around
· I would be shocked if they liquidated without announcing a target
· I love the industrial/infrastructure play and expect something “green energy” related
· Warrant is one full share - 1:1
Structure:
Ellenoff Grossman & Schole LLP – Number one SPAC lawyers last yearSkadden, Arps, Slate, Meagher & Flom LLP – Number five last yearNomura, Stifel – haven’t heard much from this UW team (only one SPAC deal)300m in trust - 100% still in itSeptember 3rd Deadline
Additional Terms:
  1. Crescent Term: $9.20 threshold
  2. Anchor Investor: BlackRock $32.5M
  3. Forward Purchase: Nomura $125M

From the S1:
“We intend to focus on industries that complement our management team’s background, and to capitalize on the ability of our management team to identify and acquire a business**, focusing on industrial, infrastructure solutions and value-added distribution sectors** in the United States (which may include a business based in the United States which has operations or opportunities outside of the United States). We will seek to acquire one or more businesses with an aggregate enterprise value of $750 million or greater.”

![img](y4n9vlod55851 " ")
https://preview.redd.it/p9sbx6he55851.png?width=566&format=png&auto=webp&s=e9eb1c404f31d2a1092451289eb00e374fe1cd02
Managment/Leadership:Daniel J. Hennessy, our Chairman and Chief Executive Officer since our formation, is also the Managing Member of Hennessy Capital LLC, an alternative investment firm he established in 2013. From September 2013 to February 2015, Mr. Hennessy served as Chairman of the Board and Chief Executive Officer of Hennessy Capital Acquisition Corp., or Hennessy I, which merged with School Bus Holdings Inc. in February 2015 and is now known as Blue Bird Corporation (NASDAQ: BLBD), and since February 2015, has served as its Vice Chairman. From April 2015 to February 2017, Mr. Hennessy served as Chairman of the Board and Chief Executive Officer of Hennessy Capital Acquisition Corp. II, or Hennessy II, which merged with Daseke in February 2017 and is now known as Daseke, Inc. (NASDAQ: DSKE) and since February 2017, has served as its Vice Chairman. Since August 2018, Mr. Hennessy has served as a director of SIRVA Worldwide Relocation & Moving. From January 2017 to October 2018, Mr. Hennessy served as Chairman of the Board and Chief Executive Officer of Hennessy III, which merged with NRC Group Holdings, LLC, a global provider of comprehensive environmental, compliance and waste management services, in October 2018 and is now known as NRC Group Holdings Corp. (NYSE American: NRCG) and since October 2018, has served as a director. From 1988 to 2016, Mr. Hennessy served as a Partner at Code Hennessy & Simmons LLC (n/k/a CHS Capital or “CHS”), a middle-market private equity investment firm he co-founded in 1988. Over a 25 year period, CHS invested $2.9 billion in nearly 400 operating companies. Mr. Hennessy has served as Chairman of the Board of Directors of various CHS portfolio companies that manufacture and/or distribute a broad array of products or provide services for the industrial, infrastructure, energy and packaging sectors. In 2009, EDH Properties, LLC, a family real estate investment entity for which Mr. Hennessy was the managing member, filed a petition for voluntary reorganization under Chapter 11 of the U.S. Bankruptcy Code. A plan of reorganization was confirmed by the court in 2010 and the lender received payment in full. Prior to forming CHS, Mr. Hennessy was employed by Citicorp from 1984 to 1988 as head of the Midwest Region for Citicorp Mezzanine Investments and Vice President and Team Leader with Citicorp Leveraged Capital Group. He began his career in 1981 in the oil and gas lending group at Continental Illinois National Bank (now Bank of America) where he was a Banking Officer. Mr. Hennessy holds a B.A. degree, magna cum laude, from Boston College and an M.B.A. from the University of Michigan Ross School of Business. Mr. Hennessy is well qualified to serve as director due to his experience in private equity and public and private company board governance, as well as his background in finance and his experience with Hennessy I, Hennessy II and Hennessy III.
Greg Ethridge, who will be our President, Chief Operating Officer and director as of the effective date of the registration statement of which this prospectus forms a part, served as President of Matlin & Partners Acquisition Corporation from January 2017 to November 2018, at which time it merged with USWS Holdings LLC, a growth- and technology-oriented oilfield service company focused exclusively on hydraulic fracturing for oil and natural gas exploration and production companies and is now known as U.S. Well Services, Inc. (NASDAQ: USWS). He serves as Senior Partner of MatlinPatterson Global Advisers LLC, or MatlinPatterson. Prior to joining MatlinPatterson in 2009, Mr. Ethridge was a principal in the Recapitalization and Restructuring group at Broadpoint Capital, Inc. where he moved his team from Imperial Capital LLC, from 2008 to 2009. In 2006, Mr. Ethridge was a founding member of the corporate finance advisory practice for Imperial Capital LLC in New York. From 2005 to 2006, Mr. Ethridge was a principal investor at Parallel Investment Partners LP (formerly part of Saunders, Karp and Megrue), executing recapitalizations, 110 buyouts and growth equity investments for middle market companies. From 2001 to 2005, Mr. Ethridge was an associate in the Recapitalization and Restructuring Group at Jefferies and Company, Inc. where he executed corporate restructurings and leveraged finance transactions and was a crisis manager at Conway, Del Genio, Gries & Co. in New York from 2000 to 2001. Mr. Ethridge has served a director of Palmetto Bluff Company, LLC, formerly a multi-asset class real estate developer known as Crescent Communities, LLC, a multi-class real estate developer, since June 2010. From 2009 until 2017, Mr. Ethridge served on the board of directors of FXI Holdings Inc., a foam and foam products manufacturer and served as its chairman from February 2012 until 2017. Mr. Ethridge has also served on the board of directors of Advantix Systems Ltd. and Advantix Systems, Inc., HVAC equipment manufacturers, from August 2013 until 2015 (for Advantix Systems, Inc.) and until 2018 (for Advantix Systems Ltd.). Mr. Ethridge holds a BBA and a Masters in Accounting from The University of Texas at Austin. Mr. Ethridge is well-qualified to serve as director due to his experience in the private equity and the special purpose acquisition company industries.
Nicholas A. Petruska, our Executive Vice President, Chief Financial Officer and Secretary since our formation, has served as the Vice President of Hennessy Capital LLC, the managing member of our Sponsor, since November 2013, in which position he advised Hennessy I, which merged with School Bus Holdings Inc. in February 2015 and is now known as Blue Bird Corporation (NASDAQ: BLBD), in connection with its initial public offering in January 2014. In addition, he worked closely with Hennessy I’s CEO and COO on transaction origination and initial assessments of potential target companies and led the due diligence assessment and transaction execution for Hennessy 1’s business combination, which was consummated in February 2015. From April 2015 to February 2017, Mr. Petruska served as Chief Financial Officer of Hennessy II, which merged with Daseke in February 2017 and is now known as Daseke Inc. (NASDAQ: DSKE). From March 2017 to October 2018, Mr. Petruska served as Executive Vice President, Chief Financial Officer and Secretary of Hennessy III. From July 2012 to July 2014, Mr. Petruska served as an associate at CHS Capital, a Chicago-based middle market private equity investment firm, where he evaluated leveraged buyouts and structured equity investments across multiple sectors and monitored certain portfolio companies of CHS. From January 2010 to July 2012, Mr. Petruska served as an investment banking analyst for Morgan Stanley (NYSE: MS) in the mergers and acquisitions and corporate finance groups with a focus on diversified industrials and consumer retail. He holds a B.S. degree, summa cum laude, from Miami University with majors in Finance and Decision Sciences.
Bradley Bell will be one of our independent directors as of the effective date of the registration statement of which this prospectus forms a part, and will serve as the chairman of our audit committee. From January 2014 to February 2015, Mr. Bell served as a director and chairman of the Audit Committee of Hennessy I, which merged with School Bus Holdings Inc. in February 2015 and is now known as Blue Bird Corporation (NASDAQ: BLBD). From July 2015 to February 2017, Mr. Bell served as a director and chairman of the Audit Committee of Hennessy II, which merged with Daseke in February 2017 and is now known as Daseke, Inc. (NASDAQ: DSKE). From June 2017 to October 2018, Mr. Bell served as a director and chairman of the audit committee of Hennessy III. Since October 2014, Mr. Bell has served as a director of MPM Holdings, Inc., a global manufacturer of silicones and quartz products, where he has been Non-Executive Chair since December 2014. Since July 2015, Mr. Bell has served as a director and Chairman of the Audit Committee of The Chemours Company LLC (NYSE: CC), a chemical solutions company. From 2001 through 2015, he served as a director of IDEX Corporation (NYSE: IEX), a global industrial company with key growth platforms in Fluid Metering Technology and Health & Science Technology segments, where he chaired the Nominating and Corporate Governance Committee and Audit Committee and served on the Compensation Committee. From December 2003 through July 2015, he served as a director of Compass Minerals Corporation (NYSE: CMP), an international mining company with operations in salt and specialty nutrients, where he chaired the Compensation Committee and Audit Committee and served on the Nominating and Corporate Governance Committee. From 2009 to 2015, he served as a director and Chairman of the Audit Committee of Coskata Company, a pre-revenue biomass startup with proprietary technology for the production of fuels and chemicals utilizing anaerobic microorganisms. From 2011 to 2014, Mr. Bell served as a director and chairman of the Audit Committee of Virent Corporation, a pre-revenue biochemical company with proprietary technology for producing plastics and other products from plant sugars. From November 2003 to December 2010, Mr. Bell served as Executive Vice President of Nalco Corporation, an industrial water treatment and energy services company. Mr. Bell has over 30 years combined experience as an executive in the technology and manufacturing industries, including positions at Rohm and Haas Company, Whirlpool Corporation and Bundy Corporation. Through his experience, Mr. Bell has developed financial expertise and experience in mergers and acquisitions, private equity and capital markets transactions. He has held directorships at publicly traded companies for over 25 years, during which he chaired governance, audit and compensation committees. Through his executive experience and board memberships, Mr. Bell has acquired training and experience in corporate governance and executive compensation. Mr. Bell received a B.S. in finance with high honors from the University of Illinois and a master of business administration degree with distinction from Harvard University. Mr. Bell is well qualified to serve as director due to his experience in public and private company governance and accounting, including his service on audit, nominating and corporate governance and compensation committees, including his experience with Hennessy I, Hennessy II and Hennessy III.
Richard Burns will be one of our independent directors as of the effective date of the registration statement of which this prospectus forms a part. From January 2014 to February 2015, Mr. Burns served as a director of Hennessy I, which merged with School Bus Holdings Inc. in February 2015 and is now known as Blue Bird Corporation (NASDAQ: BLBD). From July 2015 to February 2017, Mr. Burns served as a director of Hennessy II, which merged with Daseke in February 2017 and is now known as Daseke, Inc. (NASDAQ: DSKE). From June 2017 to October 2018, Mr. Burns served as a director of Hennessy III. He also serves as a Senior Advisor to McKinsey & Company, consulting with telecom service providers, suppliers, and private equity investors, and has done so since April 2008. Mr. Burns also serves on the board of GeorgiasOwn Credit Union, a consumer retail financial services firm, since 2002. He served on the board of Unison Site Management, a cell site management firm, from March 2010 to June 2016. Mr. Burns has over 35 years of combined executive experience in telecommunications, including landline, broadband and wireless networks. He served as an officer of BellSouth from 2002 to 2006, holding a number of positions including Chief Integration Officer for Broadband Transformation, President of Bellsouth Broadband and Internet Services, and Chief Supply Chain Officer. He also served as an officer of AT&T from December 2006 to March 2008, as President of AT&T’s Wireless Network. Through his experience, Mr. Burns has developed expertise in operations, mergers, financial management, and private equity investment. Through his executive experience and board service Mr. Burns has acquired both experience and training in corporate governance, executive compensation, and finance. Mr. Burns received both his Bachelor and Master’s Degrees in Engineering from the University of Louisville, and an MBA from Vanderbilt University with Honors. Mr. Burns is well qualified to serve as a director due to his executive experience in large public companies, as well as his board experience in privately held firms and Hennessy I, Hennessy II and Hennessy III.
Juan Carlos Mas will be one of our independent directors as of the effective date of the registration statement of which this prospectus forms a part. Since April 2011, Mr. Mas serves as the chairman of The Mas Group, a company that invests in various industries including infrastructure development, real estate, construction equipment and healthcare. He has also served as chairman and founder of Synergy Rents, a construction equipment rental company, since April 2013. Mr. Mas is a member of the board of directors of CareCloud, a software and services company for the healthcare industry, and chairman of Cross Country Infrastructure Services, a supplier of materials, tools, parts and equipment for the oil and gas pipeline construction industry. From January 2002 to June 2007, Mr. Mas served as chairman and chief executive officer of Neff Corporation, a construction equipment rental company. From July 1990 to January 2002, Mr. Mas served in a variety of executive positions at MasTec, Inc. (NYSE: MTZ), including as President of MasTec International. Mr. Mas holds BBA and JD degrees from the University of Miami. Mr. Mas is well qualified to serve as a director due to his extensive experience as a founder, executive office and director of numerous industrial companies as well as his significant experience investing in industrial companies.
Gretchen W. McClain will be one of our independent directors as of the effective date of the registration statement of which this prospectus forms a part. Since June 2014, Ms. McClain has served as principal of G. W. Advisory Services, a consulting business providing leadership coaching and business advisory services to executives to help them grow their businesses and expand their leadership capabilities. Ms. McClain was the founding President and Chief Executive Officer of Xylem, Inc. (NYSE: XYL) from October 2011 to September 2013. She joined Xylem as the founding CEO in 2011 when it was formed and taken public from a spinoff of the water business of ITT Corporation. She joined ITT Corporation in 2005 as the president of its residential and commercial water business and served as the senior vice president and president of its commercial businesses from 2008 to 2011. Ms. McClain has served in a number of senior executive positions at Honeywell Aerospace (formerly AlliedSignal), including vice president and general manager of the business, general aviation and helicopters electronics division, and vice president for engineering and technology, as well as for program management in Honeywell Aerospace’s engines, systems and services division. She also spent nine years with NASA and served as Deputy Associate Administrator for Space Development, where she played a pivotal role in the successful development and launch of the International Space Station Program as Chief Director of the Space Station and Deputy Director for Space Flight. She currently serves as a director of Ametek, Inc. (NYSE: AME), Booz Allen Hamilton Holding Corporation (NYSE: BAH), Boart Longyear Limited (ASX: BLY), and J.M. Huber Corporation (a family-owned business), and previously served as a director of Xylem from 2011 to 2013 and Con-Way Inc. from June 2015 to October 2015. Ms. McClain holds a B.S. in Mechanical Engineering from the University of Utah. Ms. McClain is well qualified to serve as a director due to her extensive business, developmental, strategic and technical background from more than 25 years of global experience across multiple industries, including as CEO of a publicly traded industrial company and government agency leadership.
James F. O’Neil III will be one of our independent directors as of the effective date of the registration statement of which this prospectus forms a part. Since June 2017, Mr. O’Neil has served as a director of Hennessy III, which merged with NRC Group Holdings, LLC, a global provider of comprehensive environmental, compliance and waste management services, in October 2018 and is now known as NRC Group Holdings Corp. (NYSE American: NRCG). He was a Partner of Western Commerce Group from April 2016 to March 2018. In October 2017, Mr. O’Neil formed Forefront Solutions, LLC, a consulting company to the energy infrastructure industry. Mr. O’Neil served as the Chief Executive Officer and President of Quanta Services, Inc. from May 2011 to March 2016 and from October 2008 to March 2016, respectively. He previously served as Chief Operating Officer of Quanta Services from October 2008 to 2011. Earlier, Mr. O’Neil served as a Senior Vice President of Quanta Services with responsibility for Operations Integration & Audit from December 2002 to October 2008. He served as a Vice President of Operations Integration at Quanta Services from August 1999 to December 2002. Mr. O’Neil joined Quanta in 1999 and, throughout his tenure at Quanta, was responsible for various initiatives, including: renewable energy strategy; commercial and industrial operations; internal audit; and merger and acquisition initiatives, including oversight of the acquisition and integration of InfraSource, its largest acquisition. From 1980 to 1999, Mr. O’Neil held various positions with Halliburton Company, a provider of products and services to the petroleum and energy industries, lastly as Director, Global Deepwater Development. Mr. O’Neil has been a Director of FirstEnergy Corp. since January 2017. He also served as a Director of Quanta Services, Inc. from May 2011 to March 2016. Mr. O’Neil holds a B.S. in Civil Engineering from Tulane University, New Orleans in 1980. Mr. O’Neil is well qualified to serve as a director due to his extensive experience in commercial and industrial operations and with mergers and acquisitions execution and integration and his experience with Hennessy III.
Peter Shea will be one of our independent directors as of the effective date of the registration statement of which this prospectus forms a part, and will serve as the chairman of our compensation committee. From January 2014 to February 2015, Mr. Shea served as a director and chairman of the Compensation Committee of Hennessy I, which merged with School Bus Holdings Inc. in February 2015 and is now known as Blue Bird Corporation (NASDAQ: BLBD). From July 2015 to February 2017, Mr. Shea served as a director and chairman of the Compensation Committee of Hennessy II, which merged with Daseke in February 2017 and is now known as Daseke, Inc. (NASDAQ: DSKE). From June 2017 to October 2018, Mr. Shea has served as a director and chairman of the compensation committee of Hennessy III. Since January 2010, Mr. Shea has been a private equity advisor and an independent director for various companies. He has served as an operating partner of Snow Phipps Group, a private equity firm, since April 2013. He has been a director of Viskase Companies (OTCMKTS: VKSC), a supplier of cellulose and fibrous casings since October 2006, where he is currently chairman of the Audit Committee and previously served as chairman of the Compensation Committee. He has been a director of CVR Partners LP (NYSE: UAN), a nitrogen fertilizer producer, since May 2014 where he is currently Chairman of the Environmental, Health and Safety Committee and a member of the Audit Committee. Since September 2015, Mr. Shea has served as chairman of the board of directors of Voltari Corporation (NASDAQ: VLTC), a commercial real estate company. Since May 2014, Mr. Shea has served as Chairman of the Board of Directors of FeraDyne Outdoors LLC, a private company which manufactures hunting and fishing accessories. Since November 2014, he has served as Chairman of Teasedale Foods, a private company and a processor of Hispanic food products. Since September 2017, Mr. Shea has served as Chairman of Decopac Inc., a private company, which is a B2B food processing supplier. Mr. Shea served as a Director of Trump Entertainment Resorts LLP from January 2016 to June 2017, where he was a member of the Audit Committee. From November 2011 to December 2016, Mr. Shea was an operating advisor for OMERS Private Equity. He served as a Director of Give and Go Prepared Foods, a food processor, from January 2012 until July 2016. He was a Director of CTI Foods, a processor of protein and soup products from May 2010 to July 2013. He previously served as a director of, Sitel Worldwide Corporation, a customer relationship marketing business, from October 2011 until September 2015. Mr. Shea has also served as a Director, Chairman, Executive Chairman, Chief Executive Officer, President or Managing Director of a variety of companies including Icahn Enterprises, H.J. Heinz Company Europe, John Morrell & Company, Specialty Meats Company, Grupo Polymer United Latin America, Roncadin GmbH, Premium Standard Farms, New Energy Company of Indiana and United Brands Company where he was Head of Global Corporate Development. He has an MBA from the University of Southern California and a BBA from Iona College. Mr. Shea is well qualified to serve as a director due to his experience in public and private company governance and private equity, including his service on numerous corporate boards and on audit and compensation committees, including his experience with Hennessy I, Hennessy II and Hennessy III.
https://www.sec.gov/Archives/edgadata/1750153/000121390019002115/0001213900-19-002115-index.htm
https://www.nasdaq.com/market-activity/stocks/hcac/institutional-holdings
http://www.hennessycapllc.com/
TLDR: HCAC has strong leadership and institutional ties, this is the groups 4th SPAC and I expect a target announcement within the next 6 weeks
Disclaimer: Yes I have a position and this is by no means financial advise Edit: Corrected warrant value
submitted by GhostfacexProdigy to SPACs [link] [comments]

Celebs Go Dating  FULL Episode  Series 1, Episode 1 L.T.D.-love ballad WORKING Celebs Go Dating Series 2 Episode 8 FULL EPISODE Celebs Go Dating - YouTube LTD - Holding On (When Love Is Gone)

GoGaga is a new age dating app that connects you with trustworthy singles in your extended social circles. Ask your friend to set you up with someone they think you would connect well with. Join the fun of matchmaking and being a wingperson for your friends at GoGaga. GO DATING LTD - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, charges, business activity Dating sites are tagged as having historically high failure rates and a hint of business hustle, so they are avoided by professional investors. Others in this category would include online People for GO DATING LTD (04546749) More for GO DATING LTD (04546749) Registered office address Suite 8 46 Dorset Street, London, England, W1U 7NB . Company status Active Company type Private limited Company Incorporated on 26 September 2002. Accounts. Next accounts made up to Your all in one solution to grow online. Create your own free website, get a domain name, fast hosting, online marketing and award-winning 24/7 support.

[index] [11] [95] [55] [49] [79] [90] [92] [76] [37] [51]

Celebs Go Dating FULL Episode Series 1, Episode 1

Sam Craske And Olivia Attwood Break The Agency Rules And Have Their First Kiss! Celebs Go Dating by Celebs Go Dating. 4:14. The BEST (or WORST?) Moments from Week 4 (FINAL WEEK)! Celebs Go Dating Song Love Ballad; Artist L.T.D. Writers Skip Scarborough; Licensed to YouTube by UMG (on behalf of A&M); CMRRA, PEDL, LatinAutor, UNIAO BRASILEIRA DE EDITORAS DE MUSICA - UBEM, LatinAutor - Warner ... WORKING Celebs Go Dating Series 2 Episode 11 FULL EPISODE - Duration: 46:29. FlightLevel 300 66,703 views. 46:29. BEST of Series 7 with Jack Fincham, Megan Barton-Hanson & More!! ... Meanwhile, Go Dating is back with a difference as the romance experts are guiding stars through dating in the time of coronavirus. The hit E4 series is pushing ahead with a new series despite the ... FULL Celebs Go Dating Series 2 Episode 1 WORKING Episode - Duration: 46:28. FlightLevel 300 224,688 views. 46:28.